1,587 results on '"Reingold, Arthur"'
Search Results
2. Anticipated and Experienced Stigma After Testing Positive for SARS-CoV-2: A Qualitative Study.
- Author
-
De Zuzuarregui, Mariah, Frank, Darren, Gomez-Aladino, Sarah, Muñoz, Ariel, Williamson, Sabrina, Wang, Emily, Hunter, Lauren, Packel, Laura, Reingold, Arthur, and Facente, Shelley
- Subjects
COVID-19 ,SARS-CoV-2 ,public health messaging ,qualitative research ,stigma ,Humans ,SARS-CoV-2 ,COVID-19 ,COVID-19 Testing ,Pandemics ,Social Stigma - Abstract
INTRODUCTION: Stigma has inhibited public health practitioners influence during the COVID-19 pandemic. We explore the experienced and anticipated stigma of people affiliated with a large university in the United States, using the Health Stigma and Discrimination Framework. METHODS: We conducted a qualitative secondary substudy of 20 people who tested SARS-CoV-2 positive and 10 who tested negative in the summer of 2020, selected from a study of 3,324 university students and employees. FINDINGS: No participants reported anticipated stigmatization prior to testing positive. However, eight of 20 participants recounted stigma marking (being marked by COVID-19 diagnosis or membership in a high-risk group) or manifestations of stigma after testing positive, including feelings of guilt or shame, and concerns about being judged as selfish or irresponsible. Three described being denied services or social interactions as a result of having had COVID-19, long after their infectiousness ended. Participants noted that clear public health messaging must be paired with detailed scientific information, rather than leaving people to resort to non-experts to understand the science. DISCUSSION: Public health messaging designed to mitigate spread of SARS-CoV-2 and protect the community may perpetuate stigma and exacerbate inequities. As a result, people may avoid testing or treatment, mistrust public health messaging, or even use risk-increasing behavior as coping mechanisms. IMPLICATIONS FOR PRACTICE: Intentional use of language that promotes equity and deters discrimination must be high priority for any COVID-19-related public health messaging. Partnership with community leaders to co-create programs and disseminate messaging is a critical strategy for reducing stigma, especially for historically mistreated groups.
- Published
- 2024
3. Meningococcal Disease in Persons With HIV Reported Through Active Surveillance in the United States, 2009-2019.
- Author
-
Rudmann, Keegan, Cooper, Gabrielle, Marjuki, Henju, Reingold, Arthur, Barnes, Meghan, Petit, Susan, Moore, Ashley, Harrison, Lee, Lynfield, Ruth, Khanlian, Sarah, Anderson, Bridget, Martin, Tasha, Schaffner, William, McNamara, Lucy, and Rubis, Amy
- Subjects
Neisseria meningitidis ,invasive meningococcal disease ,people with HIV - Abstract
Persons with HIV (PWH) are at increased risk for bacterial infections, and previous publications document an increased risk for invasive meningococcal disease (IMD) in particular. This analysis provides evidence that PWH face a 6-fold increase in risk for IMD based on Active Bacterial Core surveillance data collected during 2009-2019.
- Published
- 2024
4. Severity of influenza-associated hospitalisations by influenza virus type and subtype in the USA, 2010-19: a repeated cross-sectional study.
- Author
-
Sumner, Kelsey, Masalovich, Svetlana, OHalloran, Alissa, Holstein, Rachel, Reingold, Arthur, Kirley, Pam, Alden, Nisha, Herlihy, Rachel, Meek, James, Yousey-Hindes, Kimberly, Anderson, Evan, Openo, Kyle, Monroe, Maya, Leegwater, Lauren, Henderson, Justin, Lynfield, Ruth, McMahon, Melissa, McMullen, Chelsea, Angeles, Kathy, Spina, Nancy, Engesser, Kerianne, Bennett, Nancy, Felsen, Christina, Lung, Krista, Shiltz, Eli, Thomas, Ann, Talbot, H, Schaffner, William, Swain, Ashley, George, Andrea, Rolfes, Melissa, Reed, Carrie, and Garg, Shikha
- Subjects
Humans ,United States ,Influenza ,Human ,Influenza Vaccines ,Cross-Sectional Studies ,Influenza A Virus ,H3N2 Subtype ,Influenza A Virus ,H1N1 Subtype ,Influenza B virus ,Influenza A virus ,Hospitalization - Abstract
BACKGROUND: Influenza burden varies across seasons, partly due to differences in circulating influenza virus types or subtypes. Using data from the US population-based surveillance system, Influenza Hospitalization Surveillance Network (FluSurv-NET), we aimed to assess the severity of influenza-associated outcomes in individuals hospitalised with laboratory-confirmed influenza virus infections during the 2010-11 to 2018-19 influenza seasons. METHODS: To evaluate the association between influenza virus type or subtype causing the infection (influenza A H3N2, A H1N1pdm09, and B viruses) and in-hospital severity outcomes (intensive care unit [ICU] admission, use of mechanical ventilation or extracorporeal membrane oxygenation [ECMO], and death), we used FluSurv-NET to capture data for laboratory-confirmed influenza-associated hospitalisations from the 2010-11 to 2018-19 influenza seasons for individuals of all ages living in select counties in 13 US states. All individuals had to have an influenza virus test within 14 days before or during their hospital stay and an admission date between Oct 1 and April 30 of an influenza season. Exclusion criteria were individuals who did not have a complete chart review; cases from sites that contributed data for three or fewer seasons; hospital-onset cases; cases with unidentified influenza type; cases of multiple influenza virus type or subtype co-infection; or individuals younger than 6 months and ineligible for the influenza vaccine. Logistic regression models adjusted for influenza season, influenza vaccination status, age, and FluSurv-NET site compared odds of in-hospital severity by virus type or subtype. When missing, influenza A subtypes were imputed using chained equations of known subtypes by season. FINDINGS: Data for 122 941 individuals hospitalised with influenza were captured in FluSurv-NET from the 2010-11 to 2018-19 seasons; after exclusions were applied, 107 941 individuals remained and underwent influenza A virus imputation when missing A subtype (43·4%). After imputation, data for 104 969 remained and were included in the final analytic sample. Averaging across imputed datasets, 57·7% (weighted percentage) had influenza A H3N2, 24·6% had influenza A H1N1pdm09, and 17·7% had influenza B virus infections; 16·7% required ICU admission, 6·5% received mechanical ventilation or ECMO, and 3·0% died (95% CIs had a range of less than 0·1% and are not displayed). Individuals with A H1N1pdm09 had higher odds of in-hospital severe outcomes than those with A H3N2: adjusted odds ratios (ORs) for A H1N1pdm09 versus A H3N2 were 1·42 (95% CI 1·32-1·52) for ICU admission; 1·79 (1·60-2·00) for mechanical ventilation or ECMO use; and 1·25 (1·07-1·46) for death. The adjusted ORs for individuals infected with influenza B versus influenza A H3N2 were 1·06 (95% CI 1·01-1·12) for ICU admission, 1·14 (1·05-1·24) for mechanical ventilation or ECMO use, and 1·18 (1·07-1·31) for death. INTERPRETATION: Despite a higher burden of hospitalisations with influenza A H3N2, we found an increased likelihood of in-hospital severe outcomes in individuals hospitalised with influenza A H1N1pdm09 or influenza B virus. Thus, it is important for individuals to receive an annual influenza vaccine and for health-care providers to provide early antiviral treatment for patients with suspected influenza who are at increased risk of severe outcomes, not only when there is high influenza A H3N2 virus circulation but also when influenza A H1N1pdm09 and influenza B viruses are circulating. FUNDING: The US Centers for Disease Control and Prevention.
- Published
- 2023
5. COVID-19-Associated Hospitalizations Among U.S. Adults Aged ≥65 Years - COVID-NET, 13 States, January-August 2023.
- Author
-
Taylor, Christopher, Patel, Kadam, Patton, Monica, Kawasaki, Breanna, Meek, James, Openo, Kyle, Ryan, Patricia, Falkowski, Anna, Bye, Erica, Plymesser, Kelly, Spina, Nancy, Tesini, Brenda, Moran, Nancy, Sutton, Melissa, Talbot, H, George, Andrea, Havers, Fiona, and Reingold, Arthur
- Subjects
Humans ,Adult ,United States ,COVID-19 ,SARS-CoV-2 ,Hospitalization ,Intensive Care Units ,Vaccination - Abstract
Adults aged ≥65 years remain at elevated risk for severe COVID-19 disease and have higher COVID-19-associated hospitalization rates compared with those in younger age groups. Data from the COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) were analyzed to estimate COVID-19-associated hospitalization rates during January-August 2023 and identify demographic and clinical characteristics of hospitalized patients aged ≥65 years during January-June 2023. Among adults aged ≥65 years, hospitalization rates more than doubled, from 6.8 per 100,000 during the week ending July 15 to 16.4 per 100,000 during the week ending August 26, 2023. Across all age groups, adults aged ≥65 years accounted for 62.9% (95% CI = 60.1%-65.7%) of COVID-19-associated hospitalizations, 61.3% (95% CI = 54.7%-67.6%) of intensive care unit admissions, and 87.9% (95% CI = 80.5%-93.2%) of in-hospital deaths associated with COVID-19 hospitalizations. Most hospitalized adults aged ≥65 years (90.3%; 95% CI = 87.2%-92.8%) had multiple underlying conditions, and fewer than one quarter (23.5%; 95% CI = 19.5%-27.7%) had received the recommended COVID-19 bivalent vaccine. Because adults aged ≥65 years remain at increased risk for COVID-19-associated hospitalization and severe outcomes, guidance for this age group should continue to focus on measures to prevent SARS-CoV-2 infection, encourage vaccination, and promote early treatment for persons who receive a positive SARS-CoV-2 test result to reduce their risk for severe COVID-19-associated outcomes.
- Published
- 2023
6. Factors associated with depressive symptoms among returnee migrants and non-migrants working adults in Madi municipality in Nepal: a community-based cross-sectional study
- Author
-
Adhikary, Pratik, Devkota, Hridaya Raj, Reingold, Arthur L., and Ghimire, Dirgha J.
- Published
- 2024
- Full Text
- View/download PDF
7. Epidemiology of Invasive Nontypeable Haemophilus influenzae Disease-United States, 2008-2019.
- Author
-
Oliver, Sara, Rubis, Amy, Soeters, Heidi, Reingold, Arthur, Barnes, Meghan, Petit, Susan, Farley, Monica, Harrison, Lee, Como-Sabetti, Kathy, Khanlian, Sarah, Wester, Rachel, Thomas, Ann, Schaffner, William, Marjuki, Henju, Wang, Xin, and Hariri, Susan
- Subjects
Haemophilus influenzae ,Haemophilus influenzae vaccines ,epidemiology ,nontypeable Haemophilus influenzae ,Infant ,Child ,Infant ,Newborn ,Humans ,Female ,Pregnancy ,United States ,Aged ,Haemophilus influenzae ,Haemophilus Infections ,Serotyping ,Incidence ,Postpartum Period ,Infant ,Newborn ,Diseases - Abstract
BACKGROUND: Nontypeable Haemophilus influenzae (NTHi) is the most common cause of invasive H. influenzae disease in the United States (US). We evaluated the epidemiology of invasive NTHi disease in the US, including among pregnant women, infants, and people with human immunodeficiency virus (PWH). METHODS: We used data from population- and laboratory-based surveillance for invasive H. influenzae disease conducted in 10 sites to estimate national incidence of NTHi, and to describe epidemiology in women of childbearing age, infants aged ≤30 days (neonates), and PWH living in the surveillance catchment areas. H. influenzae isolates were sent to the Centers for Disease Control and Prevention for species confirmation, serotyping, and whole genome sequencing of select isolates. RESULTS: During 2008-2019, average annual NTHi incidence in the US was 1.3/100 000 population overall, 5.8/100 000 among children aged
- Published
- 2023
8. 21 Epidemiologic Research in the Setting of Outbreak Response
- Author
-
Reingold, Arthur, Sorenson, Robert A., editor, Higgs, Elizabeth S., Editor-in-Chief, Fallah, Mosoka P., Section Editor, Lurie, Nicole, Section Editor, McNay, Laura A., Section Editor, and Smith, Peter G., Section Editor
- Published
- 2024
- Full Text
- View/download PDF
9. Changes in the Incidence of Invasive Bacterial Disease During the COVID-19 Pandemic in the United States, 2014-2020.
- Author
-
Prasad, Namrata, Rhodes, Julia, Deng, Li, McCarthy, Natalie, Moline, Heidi, Baggs, James, Reddy, Sujan, Jernigan, John, Havers, Fiona, Sosin, Daniel, Thomas, Ann, Lynfield, Ruth, Schaffner, William, Reingold, Arthur, Burzlaff, Kari, Harrison, Lee, Petit, Susan, Farley, Monica, Herlihy, Rachel, Nanduri, Srinivas, Pilishvili, Tamara, McNamara, Lucy, Schrag, Stephanie, Fleming-Dutra, Katherine, Kobayashi, Miwako, and Arvay, Melissa
- Subjects
COVID-19 ,United States ,invasive bacterial disease ,nonpharmaceutical intervention ,United States ,Humans ,Infant ,Incidence ,Pandemics ,COVID-19 ,Bacterial Infections ,Streptococcus pneumoniae ,Haemophilus influenzae ,Streptococcus agalactiae - Abstract
BACKGROUND: Descriptions of changes in invasive bacterial disease (IBD) epidemiology during the coronavirus disease 2019 (COVID-19) pandemic in the United States are limited. METHODS: We investigated changes in the incidence of IBD due to Streptococcus pneumoniae, Haemophilus influenzae, group A Streptococcus (GAS), and group B Streptococcus (GBS). We defined the COVID-19 pandemic period as 1 March to 31 December 2020. We compared observed IBD incidences during the pandemic to expected incidences, consistent with January 2014 to February 2020 trends. We conducted secondary analysis of a health care database to assess changes in testing by blood and cerebrospinal fluid (CSF) culture during the pandemic. RESULTS: Compared with expected incidences, the observed incidences of IBD due to S. pneumoniae, H. influenzae, GAS, and GBS were 58%, 60%, 28%, and 12% lower during the pandemic period of 2020, respectively. Declines from expected incidences corresponded closely with implementation of COVID-19-associated nonpharmaceutical interventions (NPIs). Significant declines were observed across all age and race groups, and surveillance sites for S. pneumoniae and H. influenzae. Blood and CSF culture testing rates during the pandemic were comparable to previous years. CONCLUSIONS: NPIs likely contributed to the decline in IBD incidence in the United States in 2020; observed declines were unlikely to be driven by reductions in testing.
- Published
- 2023
10. Monitoring SARS-CoV-2 incidence and seroconversion among university students and employees: a longitudinal cohort study in California, June–August 2020
- Author
-
Hunter, Lauren A, Wyman, Stacia, Packel, Laura J, Facente, Shelley N, Li, Yi, Harte, Anna, Nicolette, Guy, Consortium, the IGI SARS-CoV-2 Testing, Di Germanio, Clara, Busch, Michael P, Reingold, Arthur L, Petersen, Maya L, Urnov, Fyodor, McDevitt, Shana, Hirsch, Ariana, Ehrenberg, Alexander, Doudna, Jennifer A, Amen, M, Barry, Kerrie W, Boyle, John M, Brook, Cara E, Choo, Seunga, Cornmesser, Dilworth, David J, Fedrigo, Indro, Friedline, Skyler E, Graham, Thomas GW, Green, Ralph, Hamilton, Jennifer R, Hochstrasser, Megan L, Hockemeyer, Dirk, Krishnappa, Netravathi, Lari, Azra, Li, Hanqin, Lin-Shiao, Enrique, Lu, Tianlin, Lyons, Elijah F, Mark, Kevin G, Martell, Lisa Argento, Martins, A Raquel O, Mitchell, Patrick S, Moehle, Erica A, Naca, Christine, Nandakumar, Divya, O’Brien, Elizabeth, Pappas, Derek J, Pestal, Kathleen, Quach, Diana L, Rubin, Benjamin E, Sachdeva, Rohan, Stahl, Elizabeth C, Syed, Abdullah Muhammad, Tan, I-Li, Tollner, Amy L, Tsuchida, Connor A, Tsui, C Kimberly, Turkalo, Timothy K, Warf, M Bryan, Whitney, Oscar N, and Witkowsky, Lea B
- Subjects
Biodefense ,Emerging Infectious Diseases ,Infectious Diseases ,Vaccine Related ,Prevention ,Clinical Research ,Infection ,Good Health and Well Being ,Humans ,SARS-CoV-2 ,COVID-19 ,Incidence ,COVID-19 Testing ,Longitudinal Studies ,Universities ,Seroconversion ,Phylogeny ,Prospective Studies ,California ,Cohort Studies ,EPIDEMIOLOGY ,Public health ,Infection control ,Epidemiology ,PUBLIC HEALTH ,IGI SARS-CoV-2 Testing Consortium ,Clinical Sciences ,Public Health and Health Services ,Other Medical and Health Sciences - Abstract
ObjectivesTo identify incident SARS-CoV-2 infections and inform effective mitigation strategies in university settings, we piloted an integrated symptom and exposure monitoring and testing system among a cohort of university students and employees.DesignProspective cohort study.SettingA public university in California from June to August 2020.Participants2180 university students and 738 university employees.Primary outcome measuresAt baseline and endline, we tested participants for active SARS-CoV-2 infection via quantitative PCR (qPCR) test and collected blood samples for antibody testing. Participants received notifications to complete additional qPCR tests throughout the study if they reported symptoms or exposures in daily surveys or were selected for surveillance testing. Viral whole genome sequencing was performed on positive qPCR samples, and phylogenetic trees were constructed with these genomes and external genomes.ResultsOver the study period, 57 students (2.6%) and 3 employees (0.4%) were diagnosed with SARS-CoV-2 infection via qPCR test. Phylogenetic analyses revealed that a super-spreader event among undergraduates in congregate housing accounted for at least 48% of cases among study participants but did not spread beyond campus. Test positivity was higher among participants who self-reported symptoms (incidence rate ratio (IRR) 12.7; 95% CI 7.4 to 21.8) or had household exposures (IRR 10.3; 95% CI 4.8 to 22.0) that triggered notifications to test. Most (91%) participants with newly identified antibodies at endline had been diagnosed with incident infection via qPCR test during the study.ConclusionsOur findings suggest that integrated monitoring systems can successfully identify and link at-risk students to SARS-CoV-2 testing. As the study took place before the evolution of highly transmissible variants and widespread availability of vaccines and rapid antigen tests, further research is necessary to adapt and evaluate similar systems in the present context.
- Published
- 2023
11. Bacterial and viral infections among adults hospitalized with COVID-19, COVID-NET, 14 states, March 2020-April 2022.
- Author
-
Armistead, Isaac, Meek, James, Anderson, Evan, Weigel, Andy, Reeg, Libby, Como-Sabetti, Kathryn, Ropp, Susan, Muse, Alison, Bushey, Sophrena, Shiltz, Eli, Sutton, Melissa, Talbot, H, Chatelain, Ryan, Havers, Fiona, Shah, Melisa, Patel, Kadam, Milucky, Jennifer, Taylor, Christopher, and Reingold, Arthur
- Subjects
COVID‐19 ,COVID‐NET ,SARS‐CoV‐2 ,bacterial coinfection ,viral coinfection ,Adult ,Humans ,Coinfection ,COVID-19 ,Influenza ,Human ,SARS-CoV-2 ,Virus Diseases ,Bacterial Infections - Abstract
BACKGROUND: Bacterial and viral infections can occur with SARS-CoV-2 infection, but prevalence, risk factors, and associated clinical outcomes are not fully understood. METHODS: We used the Coronavirus Disease 2019-Associated Hospitalization Surveillance Network (COVID-NET), a population-based surveillance system, to investigate the occurrence of bacterial and viral infections among hospitalized adults with laboratory-confirmed SARS-CoV-2 infection between March 2020 and April 2022. Clinician-driven testing for bacterial pathogens from sputum, deep respiratory, and sterile sites were included. The demographic and clinical features of those with and without bacterial infections were compared. We also describe the prevalence of viral pathogens including respiratory syncytial virus, rhinovirus/enterovirus, influenza, adenovirus, human metapneumovirus, parainfluenza viruses, and non-SARS-CoV-2 endemic coronaviruses. RESULTS: Among 36 490 hospitalized adults with COVID-19, 53.3% had bacterial cultures taken within 7 days of admission and 6.0% of these had a clinically relevant bacterial pathogen. After adjustment for demographic factors and co-morbidities, bacterial infections in patients with COVID-19 within 7 days of admission were associated with an adjusted relative risk of death 2.3 times that of patients with negative bacterial testing. Staphylococcus aureus and Gram-negative rods were the most frequently isolated bacterial pathogens. Among hospitalized adults with COVID-19, 2766 (7.6%) were tested for seven virus groups. A non-SARS-CoV-2 virus was identified in 0.9% of tested patients. CONCLUSIONS: Among patients with clinician-driven testing, 6.0% of adults hospitalized with COVID-19 were identified to have bacterial coinfections and 0.9% were identified to have viral coinfections; identification of a bacterial coinfection within 7 days of admission was associated with increased mortality.
- Published
- 2023
12. Acute Cardiac Events During COVID-19-Associated Hospitalizations.
- Author
-
Woodruff, Rebecca, Garg, Shikha, George, Mary, Patel, Kadam, Jackson, Sandra, Loustalot, Fleetwood, Wortham, Jonathan, Taylor, Christopher, Whitaker, Michael, Alden, Nisha, Meek, James, Anderson, Evan, Weigel, Andy, Henderson, Justin, Bye, Erica, Davis, Sarah, Barney, Grant, Bennett, Nancy, Shiltz, Eli, Sutton, Melissa, Talbot, H, Price, Andrea, Sperling, Laurence, Havers, Fiona, and Reingold, Arthur
- Subjects
COVID-19 ,SARS-CoV-2 ,United States ,adults ,heart diseases ,hospitalization ,Adult ,Humans ,COVID-19 ,SARS-CoV-2 ,Hospital Mortality ,Hospitalization ,Heart Diseases - Abstract
BACKGROUND: COVID-19 is associated with cardiac complications. OBJECTIVES: The purpose of this study was to estimate the prevalence, risk factors, and outcomes associated with acute cardiac events during COVID-19-associated hospitalizations among adults. METHODS: During January 2021 to November 2021, medical chart abstraction was conducted on a probability sample of adults hospitalized with laboratory-confirmed SARS-CoV-2 infection identified from 99 U.S. counties in 14 U.S. states in the COVID-19-Associated Hospitalization Surveillance Network. We calculated the prevalence of acute cardiac events (identified by International Classification of Diseases-10th Revision-Clinical Modification codes) by history of underlying cardiac disease and examined associated risk factors and disease outcomes. RESULTS: Among 8,460 adults, 11.4% (95% CI: 10.1%-12.9%) experienced an acute cardiac event during a COVID-19-associated hospitalization. Prevalence was higher among adults who had underlying cardiac disease (23.4%; 95% CI: 20.7%-26.3%) compared with those who did not (6.2%; 95% CI: 5.1%-7.6%). Acute ischemic heart disease (5.5%; 95% CI: 4.5%-6.5%) and acute heart failure (5.4%; 95% CI: 4.4%-6.6%) were the most prevalent events; 0.3% (95% CI: 0.1%-0.5%) experienced acute myocarditis or pericarditis. Risk factors varied by underlying cardiac disease status. Patients with ≥1 acute cardiac event had greater risk of intensive care unit admission (adjusted risk ratio: 1.9; 95% CI: 1.8-2.1) and in-hospital death (adjusted risk ratio: 1.7; 95% CI: 1.3-2.1) compared with those who did not. CONCLUSIONS: Acute cardiac events were common during COVID-19-associated hospitalizations, particularly among patients with underlying cardiac disease, and are associated with severe disease outcomes. Persons at greater risk for experiencing acute cardiac events during COVID-19-associated hospitalizations might benefit from more intensive clinical evaluation and monitoring during hospitalization.
- Published
- 2023
13. Comparison of Influenza and Coronavirus Disease 2019-Associated Hospitalizations Among Children Younger Than 18 Years Old in the United States: FluSurv-NET (October-April 2017-2021) and COVID-NET (October 2020-September 2021).
- Author
-
Delahoy, Miranda, Ujamaa, Dawud, Taylor, Christopher, Cummings, Charisse, Anglin, Onika, Holstein, Rachel, Milucky, Jennifer, OHalloran, Alissa, Patel, Kadam, Pham, Huong, Whitaker, Michael, Chai, Shua, Alden, Nisha, Kawasaki, Breanna, Meek, James, Yousey-Hindes, Kimberly, Anderson, Evan, Openo, Kyle, Weigel, Andy, Teno, Kenzie, Reeg, Libby, Leegwater, Lauren, Lynfield, Ruth, McMahon, Melissa, Ropp, Susan, Rudin, Dominic, Muse, Alison, Spina, Nancy, Bennett, Nancy, Popham, Kevin, Billing, Laurie, Shiltz, Eli, Sutton, Melissa, Thomas, Ann, Schaffner, William, Talbot, H, Crossland, Melanie, McCaffrey, Keegan, Hall, Aron, Burns, Erin, McMorrow, Meredith, Reed, Carrie, Havers, Fiona, Garg, Shikha, and Reingold, Arthur
- Subjects
COVID-19 ,SARS-CoV-2 ,children ,influenza ,surveillance ,Adolescent ,Child ,Humans ,United States ,Aged ,Aged ,80 and over ,Influenza ,Human ,COVID-19 ,Pandemics ,SARS-CoV-2 ,Hospitalization - Abstract
BACKGROUND: Influenza virus and SARS-CoV-2 are significant causes of respiratory illness in children. METHODS: Influenza- and COVID-19-associated hospitalizations among children
- Published
- 2023
14. Association between epidemiologic case definition categories and adverse clinical outcome in patients with Clostridiodes difficile infection in San Francisco County, California: a five-year retrospective cohort study.
- Author
-
Siraw, Bekure, Meyahnwi, Didien, and Reingold, Arthur
- Subjects
Adverse outcome ,Case definition category ,Clostridiodes difficile ,Mortality ,Recurrence ,Humans ,Community-Acquired Infections ,Retrospective Studies ,Clostridioides difficile ,Clostridium Infections ,San Francisco ,Cross Infection ,Risk Factors - Abstract
BACKGROUND: Understanding the predictors of adverse clinical outcomes following incident Clostridiodes difficile infection (CDI) can help clinicians identify which patients are at risk of complications and help prioritize the provision of their care. In this study, we assessed the associations between epidemiologic case definition categories and adverse clinical outcomes in patients with CDI in San Francisco County, California. METHODS: We conducted a retrospective cohort study using CDI surveillance data (n = 3274) from the California Emerging Infections Program for the time period 2016 to 2020. After independent associations were established, two multivariable logistic and log-binomial regression models were constructed for the final statistical analysis. RESULT: The mean cumulative incidence of CDI cases was 78.8 cases per 100,000 population. The overall recurrence rate and the 30-day all-cause mortality rate were 11.1% and 4.5%, respectively. After adjusting for potential confounders, compared to the community associated CDI cases, healthcare facility onset (AOR = 3.1; 95% CI [1.3-7]) and community-onset-healthcare facility associated (AOR = 2.4; 95% CI [1.4-4.3]) CDI cases were found to have higher odds of all-cause 30-day mortality. Community onset-healthcare facility-associated CDI case definition category was found to be significantly associated with an increased risk of recurrence of CDI (ARR = 1.7; 95% CI [1.2-2.4]). CONCLUSION: Although the incidence of community-associated CDI cases has been rising, the odds of all-cause 30-day mortality and the risk of recurrent CDI associated with these infections are lower than healthcare facility onset and community-onset healthcare facility-associated CDI cases.
- Published
- 2023
15. Water and war: The effect of functioning chlorinated water stations in reducing waterborne diseases during conflict in northwest Syria, 2017-2021.
- Author
-
Haar, Rohini, Abdelrahman, Sarah, Muzzall, Evan, Aladhan, Ibrahim, Shobak, Kasim, Kawas, Mohamad, Aksh, Aya, Reingold, Arthur, AlMhawish, Naser, and Blair, Alden
- Abstract
Since 2011, Syria has been engulfed in a complex conflict marked by both targeted and indiscriminate attacks on civilians and civilian infrastructure. Water infrastructure has been continuously targeted, exacerbating problems with contamination of and access to clean adequate drinking water, and increasing the risk of waterborne diseases. We aimed to determine whether having access to more functional and chlorinated water stations is associated with a reduced risk of waterborne disease in northwest Syria. We examined the effect of functioning chlorinated water stations on the incidence of waterborne disease in 10 districts of Northwest Syria between January 1, 2017, and June 30, 2021, using weekly reported disease surveillance data and data from a water, sanitation, and hygiene (WASH) system evaluation program of the Assistance Coordination Unit (ACU). We ran eight negative binomial models to examine the association between functioning chlorinated water stations and the incidence of four of the five waterborne diseases: acute bloody diarrhea (ABD), acute other diarrhea (AOD), acute jaundice syndrome (AJS), and severe typhoid fever (STF). Dose-response models were used to investigate how the incidence of disease can theoretically be reduced as functioning and chlorinated water stations strategically increase. Compared to areas with lower quintiles of functioning and chlorinated water stations, the rates of the four waterborne diseases were lower in areas with higher quintiles of functioning and chlorinated water stations. Exposure to functioning water stations had a stronger association with lower rates of waterborne diseases than exposure to chlorinated water stations. Dose-response models demonstrate a potential for curbing the incidence of acute diarrhea and acute jaundice syndrome. The results of this study provide an understanding of the effects of water station functionality and chlorination in conflict settings. These findings support greater prioritization of WASH activities in countries experiencing violence against civilian infrastructure.
- Published
- 2023
16. Secondary Cases of Invasive Disease Caused by Encapsulated and Nontypeable Haemophilus influenzae — 10 U.S. Jurisdictions, 2011–2018
- Author
-
Oliver, Sara E, Rubis, Amy B, Soeters, Heidi M, Reingold, Arthur, Barnes, Meghan, Petit, Susan, Moore, Ashley E, Harrison, Lee H, Lynfield, Ruth, Angeles, Kathy M, Burzlaff, Kari E, Thomas, Ann, Schaffner, William, Marjuki, Henju, Wang, Xin, and Hariri, Susan
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Infectious Diseases ,Immunization ,Prevention ,Vaccine Related ,Clinical Research ,Pediatric ,Infection ,Good Health and Well Being ,Humans ,United States ,Infant ,Haemophilus influenzae ,Incidence ,Haemophilus Infections ,Serogroup ,Anti-Bacterial Agents ,Haemophilus Vaccines ,General & Internal Medicine - Abstract
Haemophilus influenzae (Hi) can cause meningitis and other serious invasive disease. Encapsulated Hi is classified into six serotypes (a-f) based on chemical composition of the polysaccharide capsule; unencapsulated strains are termed nontypeable Hi (NTHi). Hi serotype b (Hib) was the most common cause of bacterial meningitis in children in the pre-Hib vaccine era, and secondary transmission of Hi among children (e.g., to household contacts and in child care facilities) (1,2) led to the Advisory Committee on Immunization Practices (ACIP) recommendation for antibiotic chemoprophylaxis to prevent Hib disease in certain circumstances.* High Hib vaccination coverage since the 1990s has substantially reduced Hib disease, and other serotypes now account for most Hi-associated invasive disease in the United States (3). Nevertheless, CDC does not currently recommend chemoprophylaxis for contacts of persons with invasive disease caused by serotypes other than Hib and by NTHi (non-b Hi). Given this changing epidemiology, U.S. surveillance data were reviewed to investigate secondary cases of invasive disease caused by Hi. The estimated prevalence of secondary transmission was 0.32% among persons with encapsulated Hi disease (≤60 days of one another) and 0.12% among persons with NTHi disease (≤14 days of one another). Isolates from all Hi case pairs were genetically closely related, and all patients with potential secondary infection had underlying medical conditions. These results strongly suggest that secondary transmission of non-b Hi occurs. Expansion of Hi chemoprophylaxis recommendations might be warranted to control invasive Hi disease in certain populations in the United States, but further analysis is needed to evaluate the potential benefits against the risks, such as increased antibiotic use.
- Published
- 2023
17. Workshop-based learning and networking: a scalable model for research capacity strengthening in low- and middle-income countries
- Author
-
Perier, Celine, Nasinghe, Emmanuel, Charles, Isabelle, Ssetaba, Leoson Junior, Ahyong, Vida, Bangs, Derek, Beatty, P Robert, Czudnochowski, Nadine, Diallo, Amy, Dugan, Eli, Fabius, Jacqueline M, Baker, Hildy Fong, Gardner, Jackson, Isaacs, Stephen, Joanah, Birungi, Kalantar, Katrina, Kateete, David, Knight, Matt, Krasilnikov, Maria, Krogan, Nevan J, Langelier, Chaz, Lee, Eric, Li, Lucy M, Licht, Daniel, Lien, Katie, Lyons, Zilose, Mboowa, Gerald, Mwebaza, Ivan, Mwesigwa, Savannah, Nalwadda, Geraldine, Nichols, Robert, Penaranda, Maria Elena, Petnic, Sarah, Phelps, Maira, Popper, Stephen J, Rape, Michael, Reingold, Arthur, Robbins, Richard, Rosenberg, Oren S, Savage, David F, Schildhauer, Samuel, Settles, Matthew L, Sserwadda, Ivan, Stanley, Sarah, Tato, Cristina M, Tsitsiklis, Alexandra, Van Dis, Erik, Vanaerschot, Manu, Vinden, Joanna, Cox, Jeffery S, Joloba, Moses L, and Schaletzky, Julia
- Subjects
Infectious Diseases ,Good Health and Well Being ,Partnerships for the Goals ,Capacity Building ,Developing Countries ,Global Health ,Humans ,Poverty ,Students ,Universities ,Capacity strengthening ,Africa ,Uganda ,research ,infectious diseases ,Public Health and Health Services - Abstract
Science education and research have the potential to drive profound change in low- and middle-income countries (LMICs) through encouraging innovation, attracting industry, and creating job opportunities. However, in LMICs, research capacity is often limited, and acquisition of funding and access to state-of-the-art technologies is challenging. The Alliance for Global Health and Science (the Alliance) was founded as a partnership between the University of California, Berkeley (USA) and Makerere University (Uganda), with the goal of strengthening Makerere University's capacity for bioscience research. The flagship program of the Alliance partnership is the MU/UCB Biosciences Training Program, an in-country, hands-on workshop model that trains a large number of students from Makerere University in infectious disease and molecular biology research. This approach nucleates training of larger and more diverse groups of students, development of mentoring and bi-directional research partnerships, and support of the local economy. Here, we describe the project, its conception, implementation, challenges, and outcomes of bioscience research workshops. We aim to provide a blueprint for workshop implementation, and create a valuable resource for bioscience research capacity strengthening in LMICs.
- Published
- 2022
18. Prevalence of SARS-CoV-2 and Influenza Coinfection and Clinical Characteristics Among Children and Adolescents Aged <18 Years Who Were Hospitalized or Died with Influenza — United States, 2021–22 Influenza Season
- Author
-
Adams, Katherine, Tastad, Katie J, Huang, Stacy, Ujamaa, Dawud, Kniss, Krista, Cummings, Charisse, Reingold, Arthur, Roland, Jeremy, Austin, Elizabeth, Kawasaki, Breanna, Meek, James, Yousey-Hindes, Kimberly, Anderson, Evan J, Openo, Kyle P, Reeg, Libby, Leegwater, Lauren, McMahon, Melissa, Bye, Erica, Poblete, Mayvilynne, Landis, Zachary, Spina, Nancy L, Engesser, Kerianne, Bennett, Nancy M, Gaitan, Maria A, Shiltz, Eli, Moran, Nancy, Sutton, Melissa, Abdullah, Nasreen, Schaffner, William, Talbot, H Keipp, Olsen, Kristen, Staten, Holly, Taylor, Christopher A, Havers, Fiona P, Reed, Carrie, Budd, Alicia, Garg, Shikha, O’Halloran, Alissa, and Brammer, Lynnette
- Subjects
Influenza ,Pediatric ,Immunization ,Infectious Diseases ,Biodefense ,Emerging Infectious Diseases ,Vaccine Related ,Prevention ,Lung ,Pneumonia & Influenza ,Infection ,Good Health and Well Being ,Child ,Humans ,Adolescent ,United States ,SARS-CoV-2 ,Influenza ,Human ,Coinfection ,Seasons ,Prevalence ,COVID-19 ,Death ,General & Internal Medicine - Abstract
The 2022-23 influenza season shows an early rise in pediatric influenza-associated hospitalizations (1). SARS-CoV-2 viruses also continue to circulate (2). The current influenza season is the first with substantial co-circulation of influenza viruses and SARS-CoV-2 (3). Although both seasonal influenza viruses and SARS-CoV-2 can contribute to substantial pediatric morbidity (3-5), whether coinfection increases disease severity compared with that associated with infection with one virus alone is unknown. This report describes characteristics and prevalence of laboratory-confirmed influenza virus and SARS-CoV-2 coinfections among patients aged
- Published
- 2022
19. Epidemiologic features, clinical characteristics, and predictors of mortality in patients with candidemia in Alameda County, California; a 2017–2020 retrospective analysis
- Author
-
Meyahnwi, Didien, Siraw, Bekure B, and Reingold, Arthur
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Hematology ,Clinical Research ,Prevention ,Infectious Diseases ,Sepsis ,Good Health and Well Being ,Humans ,Aged ,Candidemia ,Retrospective Studies ,Candida ,Candida albicans ,Risk Factors ,California ,Antifungal Agents ,Bloodstream infections ,Emerging infections ,Invasive candidiasis ,Microbiology ,Medical Microbiology ,Clinical sciences ,Medical microbiology ,Public health - Abstract
BackgroundBloodstream infections caused by Candida species are responsible for significant morbidity and mortality worldwide, with an ever-changing epidemiology. We conducted this study to assess trends in the epidemiologic features, risk factors and Candida species distribution in candidemia patients in Alameda County, California.MethodsWe analyzed data collected from patients in Alameda County, California between 2017 and 2020 as part of the California Emerging Infections Program (CEIP). This is a laboratory-based, active surveillance program for candidemia. In our study, we included incident cases only.ResultsDuring the 4-year period from January 1st, 2017, to December 31st, 2020, 392 incident cases of candidemia were identified. The mean crude annual cumulative incidence was 5.9 cases per 100,000 inhabitants (range 5.0-6.5 cases per 100,000 population). Candida glabrata was the most common Candida species and was present as the only Candida species in 149 cases (38.0%), followed by Candida albicans, 130 (33.2%). Mixed Candida species were present in 13 patients (3.3%). Most of the cases of candidemia occurred in individuals with one or more underlying conditions. Multivariate regression models showed that age ≥ 65 years (RR 1.66, CI 1.28-2.14), prior administration of systemic antibiotic therapy, (RR 1.84, CI 1.06-3.17), cirrhosis of the liver, (RR 2.01, CI 1.51-2.68), and prior admission to the ICU (RR1.82, CI 1.36-2.43) were significant predictors of mortality.ConclusionsNon-albicans Candida species currently account for the majority of candidemia cases in Alameda County.
- Published
- 2022
20. Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis.
- Author
-
Huerga, Helena, Villalba, Julian, Grandjean, Louis, Sotgiu, Giovanni, Egere, Uzochukwu, Singh, Sarman, Zhu, Limei, Lienhardt, Christian, Denholm, Justin, Seddon, James, Whalen, Christopher, García-Basteiro, Alberto, Triasih, Rina, Chen, Cheng, Singh, Jitendra, Huang, Li-Min, Sharma, Surendra, Hannoun, Djohar, Del Corral, Helena, Mandalakas, Anna, Malone, LaShaunda, Ling, Du-Lin, Kritski, Afrânio, Stein, Catherine, Vashishtha, Richa, Boulahbal, Fadila, Fang, Chi-Tai, Boom, W, Netto, Eduardo, Lemos, Antonio, Hesseling, Anneke, Kay, Alexander, Jones-López, Edward, Horsburgh, C, Lange, Christoph, Andrews, Jason, Martinez, Leonardo, Cords, Olivia, Liu, Qiao, Acuna-Villaorduna, Carlos, Bonnet, Maryline, Fox, Greg, Carvalho, Anna, Chan, Pei-Chun, Croda, Julio, Hill, Philip, Lopez-Varela, Elisa, Donkor, Simon, Fielding, Katherine, Graham, Stephen, Espinal, Marcos, Kampmann, Beate, and Reingold, Arthur
- Subjects
Adolescent ,Adult ,Aged ,BCG Vaccine ,Child ,Child ,Preschool ,Humans ,Infant ,Infant ,Newborn ,Retrospective Studies ,Tuberculosis ,Tuberculosis ,Pulmonary ,Vaccination - Abstract
BACKGROUND: BCG vaccines are given to more than 100 million children every year, but there is considerable debate regarding the effectiveness of BCG vaccination in preventing tuberculosis and death, particularly among older children and adults. We therefore aimed to investigate the age-specific impact of infant BCG vaccination on tuberculosis (pulmonary and extrapulmonary) development and mortality. METHODS: In this systematic review and individual participant data meta-analysis, we searched MEDLINE, Web of Science, BIOSIS, and Embase without language restrictions for case-contact cohort studies of tuberculosis contacts published between Jan 1, 1998, and April 7, 2018. Search terms included mycobacterium tuberculosis, TB, tuberculosis, and contact. We excluded cohort studies that did not provide information on BCG vaccination or were done in countries that did not recommend BCG vaccination at birth. Individual-level participant data for a prespecified list of variables, including the characteristics of the exposed participant (contact), the index case, and the environment, were requested from authors of all eligible studies. Our primary outcome was a composite of prevalent (diagnosed at or within 90 days of baseline) and incident (diagnosed more than 90 days after baseline) tuberculosis in contacts exposed to tuberculosis. Secondary outcomes were pulmonary tuberculosis, extrapulmonary tuberculosis, and mortality. We derived adjusted odds ratios (aORs) using mixed-effects, binary, multivariable logistic regression analyses with study-level random effects, adjusting for the variable of interest, baseline age, sex, previous tuberculosis, and whether data were collected prospectively or retrospectively. We stratified our results by contact age and Mycobacterium tuberculosis infection status. This study is registered with PROSPERO, CRD42020180512. FINDINGS: We identified 14 927 original records from our database searches. We included participant-level data from 26 cohort studies done in 17 countries in our meta-analysis. Among 68 552 participants, 1782 (2·6%) developed tuberculosis (1309 [2·6%] of 49 686 BCG-vaccinated participants vs 473 [2·5%] of 18 866 unvaccinated participants). The overall effectiveness of BCG vaccination against all tuberculosis was 18% (aOR 0·82, 95% CI 0·74-0·91). When stratified by age, BCG vaccination only significantly protected against all tuberculosis in children younger than 5 years (aOR 0·63, 95% CI 0·49-0·81). Among contacts with a positive tuberculin skin test or IFNγ release assay, BCG vaccination significantly protected against tuberculosis among all participants (aOR 0·81, 95% CI 0·69-0·96), participants younger than 5 years (0·68, 0·47-0·97), and participants aged 5-9 years (0·62, 0·38-0·99). There was no protective effect among those with negative tests, unless they were younger than 5 years (0·54, 0·32-0·90). 14 cohorts reported on whether tuberculosis was pulmonary or extrapulmonary (n=57 421). BCG vaccination significantly protected against pulmonary tuberculosis among all participants (916 [2·2%] in 41 119 vaccinated participants vs 334 [2·1%] in 16 161 unvaccinated participants; aOR 0·81, 0·70-0·94) but not against extrapulmonary tuberculosis (106 [0·3%] in 40 318 vaccinated participants vs 38 [0·2%] in 15 865 unvaccinated participants; 0·96, 0·65-1·41). In the four studies with mortality data, BCG vaccination was significantly protective against death (0·25, 0·13-0·49). INTERPRETATION: Our results suggest that BCG vaccination at birth is effective at preventing tuberculosis in young children but is ineffective in adolescents and adults. Immunoprotection therefore needs to be boosted in older populations. FUNDING: National Institutes of Health.
- Published
- 2022
21. Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 — COVID-NET, 10 States, March 2020–February 2022
- Author
-
Singson, Jason Robert C, Kirley, Pam Daily, Pham, Huong, Rothrock, Gretchen, Armistead, Isaac, Meek, James, Anderson, Evan J, Reeg, Libby, Lynfield, Ruth, Ropp, Susan, Muse, Alison, Felsen, Christina B, Sutton, Melissa, Talbot, H Keipp, Havers, Fiona P, Taylor, Christopher A, Reingold, Arthur, Chai, Shua J, Alden, Nisha B, Yousey-Hindes, Kim, Openo, Kyle P, Bye, Erica, Montoya, Mark A, Barney, Grant, Popham, Kevin, Abdullah, Nasreen, and Schaffner, William
- Subjects
Prevention ,Good Health and Well Being ,Adolescent ,Adult ,COVID-19 ,COVID-19 Vaccines ,Hospital Mortality ,Hospitalization ,Humans ,Immunocompromised Host ,COVID-NET Surveillance Team ,General & Internal Medicine - Abstract
Immunocompromised persons are at increased risk for severe COVID-19-related outcomes, including intensive care unit (ICU) admission and death (1). Data on adults aged ≥18 years hospitalized with laboratory-confirmed COVID-19 from 10 U.S. states in the COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) were analyzed to assess associations between immunocompromise and ICU admission and in-hospital death during March 1, 2020-February 28, 2022. Associations of COVID-19 vaccination status with ICU admission and in-hospital death were also examined during March 1, 2021-February 28, 2022. During March 1, 2020-February 28, 2022, among a sample of 22,345 adults hospitalized for COVID-19, 12.2% were immunocompromised. Among unvaccinated patients, those with immunocompromise had higher odds of ICU admission (adjusted odds ratio [aOR] = 1.26; 95% CI = 1.08-1.49) and in-hospital death (aOR = 1.34; 95% CI = 1.05-1.70) than did nonimmunocompromised patients. Among vaccinated patients,* those with immunocompromise had higher odds of ICU admission (aOR = 1.40; 95% CI = 1.01-1.92) and in-hospital death (aOR = 1.87; 95% CI = 1.28-2.75) than did nonimmunocompromised patients. During March 1, 2021-February 28, 2022, among nonimmunocompromised patients, patients who were vaccinated had lower odds of death (aOR = 0.58; 95% CI = 0.39-0.86) than did unvaccinated patients; among immunocompromised patients, odds of death between vaccinated and unvaccinated patients did not differ. Immunocompromised persons need additional protection from COVID-19 and using multiple known COVID-19 prevention strategies,† including nonpharmaceutical interventions, up-to-date vaccination of immunocompromised persons and their close contacts,§ early testing, and COVID-19 prophylactic (Evusheld) and early antiviral treatment,¶ can help prevent hospitalization and subsequent severe COVID-19 outcomes among immunocompromised persons.
- Published
- 2022
22. Epidemiologic Features of Acute Pediatric Diarrhea in Managua, Nicaragua, from 2011 to 2019
- Author
-
Zambrana, José Victor, Carrillo, Fausto Andres Bustos, Ojeda, Sergio, Mercado, Brenda Lopez, Latta, Krista, Schiller, Amy, Kuan, Guillermina, Gordon, Aubree, Reingold, Arthur, and Harris, Eva
- Subjects
Digestive Diseases ,Pediatric Research Initiative ,Pediatric ,Prevention ,Clinical Research ,Vaccine Related ,Aetiology ,2.4 Surveillance and distribution ,Good Health and Well Being ,Adolescent ,Child ,Child ,Preschool ,Diarrhea ,Family Characteristics ,Humans ,Incidence ,Longitudinal Studies ,Nicaragua ,Prospective Studies ,Seasons ,Medical and Health Sciences ,Tropical Medicine - Abstract
Diarrhea remains a leading cause of death in children in developing countries, including Nicaragua, but little is known about patterns of diarrhea occurrence in Central America over long periods of time. The purpose of this study was to determine the incidence, risk factors, long-term trends, and seasonality of diarrhea in children age 2 to 14 years in Managua, Nicaragua. From 2011 to 2019, we examined episodes of diarrhea among 6,485 children who participated in a prospective cohort study and presented for care in a primary care facility. We performed a longitudinal analysis considering time-varying variables and the intra-subject correlation of outcomes. In addition, we analyzed the weekly incidence of diarrhea, applying seasonal trend decomposition to extract secular and seasonal patterns. The overall incidence rate of diarrhea was 133.4 episodes per 1,000 person-years (95% CI, 128.3-138.7). We observed a slight increase in the incidence of diarrhea from 2011 to 2019. Younger age was the strongest predictor of the risk of diarrhea, and incidence increased with every additional hour without running water in the household per day. Diarrhea incidence in Managua was seasonal, with high peaks each year between May and July. Despite reductions in childhood mortality since 1990 in Nicaragua, diarrheal morbidity remains a major problem in Managua.
- Published
- 2022
23. Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease Among Adults With HIV—United States, 2008–2018
- Author
-
Kobayashi, Miwako, Matanock, Almea, Xing, Wei, Adih, William K, Li, Jianmin, Gierke, Ryan, Almendares, Olivia, Reingold, Arthur, Alden, Nisha, Petit, Susan, Farley, Monica M, Harrison, Lee H, Holtzman, Corinne, Baumbach, Joan, Thomas, Ann, Schaffner, William, McGee, Lesley, and Pilishvili, Tamara
- Subjects
Infectious Diseases ,Clinical Research ,Immunization ,Prevention ,Lung ,Vaccine Related ,Infection ,Good Health and Well Being ,Adult ,Child ,HIV Infections ,Humans ,Incidence ,Infant ,Middle Aged ,Pneumococcal Infections ,Pneumococcal Vaccines ,Serogroup ,United States ,Vaccines ,Conjugate ,Young Adult ,13-valent pneumococcal conjugate vaccine ,invasive pneumococcal disease ,indirect effects ,direct effects ,HIV infection ,Clinical Sciences ,Public Health and Health Services ,Virology - Abstract
BackgroundPeople with HIV (PWH) are at increased risk for invasive pneumococcal disease (IPD). Thirteen-valent pneumococcal conjugate vaccine (PCV13) was recommended for use in US children in 2010 and for PWH aged 19 years or older in 2012. We evaluated the population-level impact of PCV13 on IPD among PWH and non-PWH aged 19 years or older.MethodsWe identified IPD cases from 2008 to 2018 through the Active Bacterial Core surveillance platform. We estimated IPD incidence using the National HIV Surveillance System and US Census Bureau data. We measured percent changes in IPD incidence from 2008 to 2009 to 2017-2018 by HIV status, age group, and vaccine serotype group, including serotypes in recently licensed 15-valent (PCV15) and 20-valent (PCV20) PCVs.ResultsIn 2008-2009 and 2017-2018, 8.4% (552/6548) and 8.0% (416/5169) of adult IPD cases were among PWH, respectively. Compared with non-PWH, a larger proportion of IPD cases among PWH were in adults aged 19-64 years (94.7%-97.4% vs. 56.0%-60.1%) and non-Hispanic Black people (62.5%-73.0% vs. 16.7%-19.2%). Overall and PCV13-type IPD incidence in PWH declined by 40.3% (95% confidence interval: -47.7 to -32.3) and 72.5% (95% confidence interval: -78.8 to -65.6), respectively. In 2017-2018, IPD incidence was 16.8 (overall) and 12.6 (PCV13 type) times higher in PWH compared with non-PWH; PCV13, PCV15/non-PCV13, and PCV20/non-PCV15 serotypes comprised 21.5%, 11.2%, and 16.5% of IPD in PWH, respectively.ConclusionsDespite reductions post-PCV13 introduction, IPD incidence among PWH remained substantially higher than among non-PWH. Higher-valent PCVs provide opportunities to reduce remaining IPD burden in PWH.
- Published
- 2022
24. Rates of respiratory syncytial virus (RSV)-associated hospitalization among adults with congestive heart failure-United States, 2015-2017.
- Author
-
Kujawski, Stephanie, Whitaker, Michael, Ritchey, Matthew, Chai, Shua, Anderson, Evan, Openo, Kyle, Monroe, Maya, Ryan, Patricia, Bye, Erica, Como-Sabetti, Kathryn, Barney, Grant, Muse, Alison, Bennett, Nancy, Felsen, Christina, Thomas, Ann, Crawford, Courtney, Talbot, H, Schaffner, William, Gerber, Susan, Langley, Gayle, Kim, Lindsay, and Reingold, Arthur
- Subjects
Adult ,Aged ,Heart Failure ,Hospitalization ,Humans ,Infant ,Influenza ,Human ,Respiratory Syncytial Virus Infections ,Respiratory Syncytial Virus ,Human ,United States - Abstract
BACKGROUND: Respiratory syncytial virus (RSV) can cause severe disease in adults with cardiopulmonary conditions, such as congestive heart failure (CHF). We quantified the rate of RSV-associated hospitalization in adults by CHF status using population-based surveillance in the United States. METHODS: Population-based surveillance for RSV (RSV-NET) was performed in 35 counties in seven sites during two respiratory seasons (2015-2017) from October 1-April 30. Adults (≥18 years) admitted to a hospital within the surveillance catchment area with laboratory-confirmed RSV identified by clinician-directed testing were included. Presence of underlying CHF was determined by medical chart abstraction. We calculated overall and age-stratified (
- Published
- 2022
25. Risky business: A mixed methods study of decision-making regarding COVID-19 risk at a public university in the United States
- Author
-
Facente, Shelley N, De Zuzuarregui, Mariah, Frank, Darren, Gomez-Aladino, Sarah, Muñoz, Ariel, Williamson, Sabrina, Wang, Emily, Hunter, Lauren, Packel, Laura, Reingold, Arthur, and Petersen, Maya
- Subjects
Biomedical and Clinical Sciences ,Psychology ,Basic Behavioral and Social Science ,Emerging Infectious Diseases ,Behavioral and Social Science ,Clinical Research ,Patient Safety ,Prevention ,Good Health and Well Being ,COVID-19 ,risk ,qualitative ,risk behaviors ,students ,Cognitive Sciences ,Biomedical and clinical sciences - Abstract
IntroductionUntil vaccines became available in late 2020, our ability to prevent the spread of COVID-19 within countries depended largely on voluntary adherence to mitigation measures. However, individual decision-making regarding acceptable COVID-19 risk is complex. To better understand decision-making regarding COVID-19 risk, we conducted a qualitative substudy within a larger Berkeley COVID-19 Safe Campus Initiative (BCSCI) during the summer of 2020, and completed a mixed-methods analysis of factors influencing decision-making.Materials and methodsWe interviewed 20 participants who tested positive for SARS-CoV-2 and 10 who remained negative, and analyzed quantitative survey data from 3,324 BCSCI participants. The BCSCI study enrolled university-affiliated people living in the local area during summer of 2020, collected data on behaviors and attitudes toward COVID-19, and conducted SARS-CoV-2 testing at baseline and endline.ResultsAt baseline, 1362 students (57.5%) and 285 non-students (35.1%) said it had been somewhat or very difficult to comply with COVID-19-related mandates. Most-cited reasons were the need to go out for food/essentials, difficulty of being away from family/friends, and loneliness. Eight interviewees explicitly noted they made decisions partially because of others who may be at high risk. We did not find significant differences between the behaviors of students and non-students.DiscussionDespite prevailing attitudes about irresponsibility of college students during the COVID-19 pandemic, students in our study demonstrated a commitment to making rational choices about risk behavior, not unlike non-students around them. Decision-making was driven by perceived susceptibility to severe disease, need for social interaction, and concern about risk to others. A harm reduction public health approach may be beneficial.
- Published
- 2022
26. Laboratory-Confirmed COVID-19–Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance — COVID-19–Associated Hospitalization Surveillance Network, 14 States, June 20, 2021–May 31, 2022
- Author
-
Havers, Fiona P, Patel, Kadam, Whitaker, Michael, Milucky, Jennifer, Reingold, Arthur, Armistead, Isaac, Meek, James, Anderson, Evan J, Weigel, Andy, Reeg, Libby, Seys, Scott, Ropp, Susan L, Spina, Nancy, Felsen, Christina B, Moran, Nancy E, Sutton, Melissa, Talbot, H Keipp, George, Andrea, Taylor, Christopher A, Daily Kirley, Pam, Alden, Nisha B, Yousey-Hindes, Kimberly, Openo, Kyle P, Brown, Chloe, Schardin, Cody T, Plymesser, Kelly, Barney, Grant, Popham, Kevin, Billing, Laurie M, Abdullah, Nasreen, Markus, Tiffanie M, and Hill, Mary
- Subjects
Clinical Research ,Infectious Diseases ,Vaccine Related ,Prevention ,Good Health and Well Being ,Adolescent ,Adult ,COVID-19 ,COVID-19 Vaccines ,Hospitalization ,Humans ,SARS-CoV-2 ,United States ,Vaccination ,COVID-NET Surveillance Team ,General & Internal Medicine - Abstract
Beginning the week of March 20–26, 2022, the Omicron BA.2 variant of SARS-CoV-2, the virus that causes COVID-19, became the predominant circulating variant in the United States, accounting for >50% of sequenced isolates.* Data from the COVID-19–Associated Hospitalization Surveillance Network (COVID-NET) were analyzed to describe recent COVID-19–associated hospitalization rates among adults aged ≥18 years during the period coinciding with BA.2 predominance (BA.2 period [Omicron BA.2 and BA.2.12.1; March 20–May 31, 2022]). Weekly hospitalization rates (hospitalizations per 100,000 population) among adults aged ≥65 years increased threefold, from 6.9 (week ending April 2, 2022) to 27.6 (week ending May 28, 2022); hospitalization rates in adults aged 18–49 and 50–64 years both increased 1.7-fold during the same time interval. Hospitalization rates among unvaccinated adults were 3.4 times as high as those among vaccinated adults. Among hospitalized nonpregnant patients in this same period, 39.1% had received a primary vaccination series and 1 booster or additional dose; 5.0% had received a primary series and ≥2 boosters or additional doses. All adults should stay up to date† with COVID-19 vaccination, and multiple nonpharmaceutical and medical prevention measures should be used to protect those at high risk for severe COVID-19 illness, irrespective of vaccination status§ (1).Beginning the week of March 20–26, 2022, the Omicron BA.2 variant of SARS-CoV-2, the virus that causes COVID-19, became the predominant circulating variant in the United States, accounting for >50% of sequenced isolates.* Data from the COVID-19–Associated Hospitalization Surveillance Network (COVID-NET) were analyzed to describe recent COVID-19–associated hospitalization rates among adults aged ≥18 years during the period coinciding with BA.2 predominance (BA.2 period [Omicron BA.2 and BA.2.12.1; March 20–May 31, 2022]). Weekly hospitalization rates (hospitalizations per 100,000 population) among adults aged ≥65 years increased threefold, from 6.9 (week ending April 2, 2022) to 27.6 (week ending May 28, 2022); hospitalization rates in adults aged 18–49 and 50–64 years both increased 1.7-fold during the same time interval. Hospitalization rates among unvaccinated adults were 3.4 times as high as those among vaccinated adults. Among hospitalized nonpregnant patients in this same period, 39.1% had received a primary vaccination series and 1 booster or additional dose; 5.0% had received a primary series and ≥2 boosters or additional doses. All adults should stay up to date† with COVID-19 vaccination, and multiple nonpharmaceutical and medical prevention measures should be used to protect those at high risk for severe COVID-19 illness, irrespective of vaccination status§ (1).
- Published
- 2022
27. Evaluation of a city-wide school-located influenza vaccination program in Oakland, California with respect to race and ethnicity: A matched cohort study.
- Author
-
Nguyen, Anna T, Arnold, Benjamin F, Kennedy, Chris J, Mishra, Kunal, Pokpongkiat, Nolan N, Seth, Anmol, Djajadi, Stephanie, Holbrook, Kate, Pan, Erica, Kirley, Pam D, Libby, Tanya, Hubbard, Alan E, Reingold, Arthur, Colford, John M, and Benjamin-Chung, Jade
- Subjects
Humans ,Influenza Vaccines ,Vaccination ,Cohort Studies ,Cross-Sectional Studies ,Schools ,Aged ,Child ,School Health Services ,California ,Influenza ,Human ,Ethnicity ,Vaccine Efficacy ,Hospitalizations ,Influenza ,School-located influenza vaccinations ,Vaccination coverage ,Vaccinations ,Immunization ,Clinical Research ,Pneumonia & Influenza ,Vaccine Related ,Emerging Infectious Diseases ,Prevention ,Biological Sciences ,Agricultural and Veterinary Sciences ,Medical and Health Sciences ,Virology - Abstract
BackgroundIncreasing influenza vaccination coverage in school-aged children may substantially reduce community transmission. School-located influenza vaccinations (SLIV) aim to promote vaccinations by increasing accessibility, which may be especially beneficial to race/ethnicity groups that face high barriers to preventative care. Here, we evaluate the effectiveness of a city-wide SLIV program by race/ethnicity from 2014 to 2018.MethodsWe used multivariate matching to pair schools in the intervention district in Oakland, CA with schools in a comparison district in West Contra Costa County, CA. We distributed cross-sectional surveys to measure caregiver-reported student vaccination status and estimated differences in vaccination coverage levels and reasons for non-vaccination between districts stratifying by race/ethnicity. We estimated difference-in-differences (DID) of laboratory confirmed influenza hospitalization incidence between districts stratified by race/ethnicity using surveillance data.ResultsDifferences in influenza vaccination coverage in the intervention vs. comparison district were larger among White (2017-18: 21.0% difference [95% CI: 9.7%, 32.3%]) and Hispanic/Latino (13.4% [8.8%, 18.0%]) students than Asian/Pacific Islander (API) (8.9% [1.3%, 16.5%]), Black (5.9% [-2.2%, 14.0%]), and multiracial (6.3% [-1.8%, 14.3%)) students. Concerns about vaccine effectiveness or safety were more common among Black and multiracial caregivers. Logistical barriers were less common in the intervention vs. comparison district, with the largest difference among White students. In both districts, hospitalizations in 2017-18 were higher in Blacks (Intervention: 111.5 hospitalizations per 100,00; Comparison: 134.1 per 100,000) vs. other races/ethnicities. All-age influenza hospitalization incidence was lower in the intervention site vs. comparison site among White/API individuals in 2016-17 (DID -25.14 per 100,000 [95% CI: -40.14, -10.14]) and 2017-18 (-36.6 per 100,000 [-52.7, -20.5]) and Black older adults in 2017-18 (-282.2 per 100,000 (-508.4, -56.1]), but not in other groups.ConclusionsSLIV was associated with higher vaccination coverage and lower influenza hospitalization, but associations varied by race/ethnicity. SLIV alone may be insufficient to ensure equitable influenza outcomes.
- Published
- 2022
28. Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States
- Author
-
Dorjee, Kunchok, Desai, Manisha, Choden, Tsering, Baxi, Sanjiv M, Hubbard, Alan E, and Reingold, Arthur L
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,HIV/AIDS ,Heart Disease ,Cardiovascular ,Heart Disease - Coronary Heart Disease ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Anti-HIV Agents ,Dideoxynucleosides ,Drug Combinations ,HIV Infections ,HIV-1 ,Humans ,Lamivudine ,Myocardial Infarction ,Tenofovir ,United States ,Human Immunodeficiency Virus ,Antiretroviral agents ,Cardiovascular disease ,Immunology ,Virology ,Clinical sciences - Abstract
IntroductionAlthough individual antiretroviral drugs have been shown to be associated with elevated cardiovascular disease (CVD) risk, data are limited on the role of antiretroviral drug combinations. Therefore, we sought to investigate CVD risk associated with antiretroviral drug combinations.MethodsUsing an administrative health-plan dataset, risk of acute myocardial infarction (AMI) associated with current exposure to antiretroviral drug combinations was assessed among persons living with HIV receiving antiretroviral therapy (ART) across the U.S. from October 2009 through December 2014. To account for confounding-by-indication and for factors simultaneously acting as causal mediators and confounders, we applied inverse probability of treatment weighted marginal structural models to longitudinal data of patients.ResultsOver 114,417 person-years (n = 73,071 persons) of ART exposure, 602 cases of AMI occurred at an event rate of 5.26 (95% CI: 4.86, 5.70)/1000 person-years. Of the 14 antiretroviral drug combinations studied, persons taking abacavir-lamivudine-darunavir had the highest incidence rate (IR: 11/1000; 95% CI: 7.4-16.0) of AMI. Risk (HR; 95% CI) of AMI was elevated for current exposure to abacavir-lamivudine-darunavir (1.91; 1.27-2.88), abacavir-lamivudine-atazanavir (1.58; 1.08-2.31), and tenofovir-emtricitabine-raltegravir (1.35; 1.07-1.71). Tenofovir-emtricitabine-efavirenz was associated with reduced risk (0.65; 0.54-0.78). Abacavir-lamivudine-darunavir was associated with increased risk of AMI beyond that expected of abacavir alone, likely attributable to darunavir co-administration. We did not find an elevated risk of AMI when abacavir-lamivudine was combined with efavirenz or raltegravir.ConclusionThe antiretroviral drug combinations abacavir-lamivudine-darunavir, abacavir-lamivudine-atazanavir and tenofovir-emtricitabine-raltegravir were found to be associated with elevated risk of AMI, while tenofovir-emtricitabine-efavirenz was associated with a lower risk. The AMI risk associated with abacavir-lamivudine-darunavir was greater than what was previously described for abacavir, which could suggest an added risk from darunavir. The results should be confirmed in additional studies.
- Published
- 2021
29. Feasibility and effectiveness of daily temperature screening to detect COVID-19 in a prospective cohort at a large public university
- Author
-
Facente, Shelley N, Hunter, Lauren A, Packel, Laura J, Li, Yi, Harte, Anna, Nicolette, Guy, McDevitt, Shana, Petersen, Maya, and Reingold, Arthur L
- Subjects
Vaccine Related ,Biodefense ,Infectious Diseases ,Clinical Research ,Prevention ,Emerging Infectious Diseases ,Infection ,Good Health and Well Being ,COVID-19 ,Feasibility Studies ,Humans ,Prospective Studies ,SARS-CoV-2 ,Temperature ,Universities ,Fever ,Temperature monitoring ,Thermometer ,Detection ,Screening ,Public Health and Health Services ,Public Health - Abstract
BackgroundMany persons with active SARS-CoV-2 infection experience mild or no symptoms, presenting barriers to COVID-19 prevention. Regular temperature screening is nonetheless used in some settings, including university campuses, to reduce transmission potential. We evaluated the potential impact of this strategy using a prospective university-affiliated cohort.MethodsBetween June and August 2020, 2912 participants were enrolled and tested for SARS-CoV-2 by PCR at least once (median: 3, range: 1-9). Participants reported temperature and symptoms daily via electronic survey using a previously owned or study-provided thermometer. We assessed feasibility and acceptability of daily temperature monitoring, calculated sensitivity and specificity of various fever-based strategies for restricting campus access to reduce transmission, and estimated the association between measured temperature and SARS-CoV-2 test positivity using a longitudinal binomial mixed model.ResultsMost participants (70.2%) did not initially have a thermometer for taking their temperature daily. Across 5481 total person months, the average daily completion rate of temperature values was 61.6% (median: 67.6%, IQR: 41.8-86.2%). Sensitivity for SARS-CoV-2 ranged from 0% (95% CI 0-9.7%) to 40.5% (95% CI 25.6-56.7%) across all strategies for self-report of possible COVID-19 symptoms on day of specimen collection, with corresponding specificity of 99.9% (95% CI 99.8-100%) to 95.3% (95% CI 94.7-95.9%). An increase of 0.1 °F in individual mean body temperature on the same day as specimen collection was associated with 1.11 increased odds of SARS-CoV-2 positivity (95% CI 1.06-1.17).ConclusionsOur study is the first, to our knowledge, that examines the feasibility, acceptability, and effectiveness of daily temperature screening in a prospective cohort during an infectious disease outbreak, and the only study to assess these strategies in a university population. Daily temperature monitoring was feasible and acceptable; however, the majority of potentially infectious individuals were not detected by temperature monitoring, suggesting that temperature screening is insufficient as a primary means of detection to reduce transmission of SARS-CoV-2.
- Published
- 2021
30. Airborne Transmission of SARS-CoV-2: What We Know
- Author
-
Samet, Jonathan M, Prather, Kimberly, Benjamin, Georges, Lakdawala, Seema, Lowe, John-Martin, Reingold, Arthur, Volckens, John, and Marr, Linsey
- Subjects
Pneumonia ,Biodefense ,Prevention ,Emerging Infectious Diseases ,Vaccine Related ,Infectious Diseases ,Pneumonia & Influenza ,Lung ,Aetiology ,2.2 Factors relating to the physical environment ,Infection ,Good Health and Well Being ,Aerosols ,COVID-19 ,Humans ,Respiratory System ,SARS-CoV-2 ,Viruses ,airborne transmission ,Biological Sciences ,Medical and Health Sciences ,Microbiology - Abstract
We examine airborne transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) potential using a source-to-dose framework beginning with generation of virus-containing droplets and aerosols and ending with virus deposition in the respiratory tract of susceptible individuals. By addressing 4 critical questions, we identify both gaps in addressing 4 critical questions with answers having policy implications.
- Published
- 2021
31. City-wide school-located influenza vaccination: A retrospective cohort study.
- Author
-
Benjamin-Chung, Jade, Arnold, Benjamin F, Mishra, Kunal, Kennedy, Chris J, Nguyen, Anna, Pokpongkiat, Nolan N, Djajadi, Stephanie, Seth, Anmol, Klein, Nicola P, Hubbard, Alan E, Reingold, Arthur, and Colford, John M
- Subjects
Humans ,Influenza Vaccines ,Vaccination ,Retrospective Studies ,Schools ,Aged ,Child ,School Health Services ,Influenza ,Human ,Influenza ,Influenza vaccination ,School-located influenza vaccination ,Vaccine Related ,Pediatric ,Pneumonia & Influenza ,Emerging Infectious Diseases ,Clinical Research ,Prevention ,Infectious Diseases ,Biological Sciences ,Agricultural and Veterinary Sciences ,Medical and Health Sciences ,Virology - Abstract
BackgroundWe measured the effectiveness of a city-wide school-located influenza vaccination (SLIV) program implemented in over 102 elementary schools in Oakland, California.MethodsWe conducted a retrospective cohort study among Kaiser Permanente Northern California (KPNC) members of all ages residing in either the intervention or a multivariate-matched comparison site from September 2011 - August 2017. Outcomes included medically attended acute respiratory illness (MAARI), influenza hospitalization, and Oseltamivir prescriptions. We estimated difference-in-differences (DIDs) in 2014-15, 2015-16, and 2016-17 using generalized linear models and adjusted for race, ethnicity, age, sex, health plan, and language.ResultsPre-intervention member characteristics were similar between sites. The proportion of KPNC members vaccinated for influenza by KPNC or the SLIV program was 8-11% higher in the intervention site than the comparison site during the intervention period. Among school-aged children, SLIV was associated with lower Oseltamivir prescriptions per 1,000 (DIDs: -3.5 (95% CI -5.5, -1.5) in 2015-16; -4.0 (95% CI -6.5, -1.6) in 2016-17) but not with other outcomes. SLIV was associated with lower MAARI per 1,000 in adults 65 + years (2014-15: -13.2, 95% CI -23.2, -3.2; 2015-16: -21.5, 95% CI -31.1, -11.9; 2016-17: -13.0, 95% CI -23.2, -2.9). There were few significant associations with other outcomes among adults.ConclusionsA city-wide SLIV intervention was associated with higher influenza vaccination coverage, lower Oseltamivir prescriptions in school-aged children, and lower MAARI among people over 65 years, suggesting possible indirect effects of SLIV among older adults.
- Published
- 2021
32. Clinical Trends Among U.S. Adults Hospitalized With COVID-19, March to December 2020
- Author
-
Garg, Shikha, Patel, Kadam, Pham, Huong, Whitaker, Michael, O'Halloran, Alissa, Milucky, Jennifer, Anglin, Onika, Kirley, Pam D, Reingold, Arthur, Kawasaki, Breanna, Herlihy, Rachel, Yousey-Hindes, Kimberly, Maslar, Amber, Anderson, Evan J, Openo, Kyle P, Weigel, Andrew, Teno, Kenzie, Ryan, Patricia A, Monroe, Maya L, Reeg, Libby, Kim, Sue, Como-Sabetti, Kathryn, Bye, Erica, Davis, Sarah Shrum, Eisenberg, Nancy, Muse, Alison, Barney, Grant, Bennett, Nancy M, Felsen, Christina B, Billing, Laurie, Shiltz, Jess, Sutton, Melissa, Abdullah, Nasreen, Talbot, H Keipp, Schaffner, William, Hill, Mary, Chatelain, Ryan, Wortham, Jonathan, Taylor, Christopher, Hall, Aron, Fry, Alicia M, Kim, Lindsay, and Havers, Fiona P
- Subjects
Aging ,Clinical Research ,Lung ,Good Health and Well Being ,Adenosine Monophosphate ,Adolescent ,Adrenal Cortex Hormones ,Adult ,Age Distribution ,Aged ,Alanine ,Antiviral Agents ,COVID-19 ,Critical Care ,Cross-Sectional Studies ,Female ,Hospitalization ,Humans ,Intensive Care Units ,Length of Stay ,Male ,Middle Aged ,Pandemics ,Respiration ,Artificial ,SARS-CoV-2 ,United States ,Vasoconstrictor Agents ,Young Adult ,Clinical Sciences ,Public Health and Health Services - Abstract
BackgroundThe COVID-19 pandemic has caused substantial morbidity and mortality.ObjectiveTo describe monthly clinical trends among adults hospitalized with COVID-19.DesignPooled cross-sectional study.Setting99 counties in 14 states participating in the Coronavirus Disease 2019-Associated Hospitalization Surveillance Network (COVID-NET).PatientsU.S. adults (aged ≥18 years) hospitalized with laboratory-confirmed COVID-19 during 1 March to 31 December 2020.MeasurementsMonthly hospitalizations, intensive care unit (ICU) admissions, and in-hospital death rates per 100 000 persons in the population; monthly trends in weighted percentages of interventions, including ICU admission, mechanical ventilation, and vasopressor use, among an age- and site-stratified random sample of hospitalized case patients.ResultsAmong 116 743 hospitalized adults with COVID-19, the median age was 62 years, 50.7% were male, and 40.8% were non-Hispanic White. Monthly rates of hospitalization (105.3 per 100 000 persons), ICU admission (20.2 per 100 000 persons), and death (11.7 per 100 000 persons) peaked during December 2020. Rates of all 3 outcomes were highest among adults aged 65 years or older, males, and Hispanic or non-Hispanic Black persons. Among 18 508 sampled hospitalized adults, use of remdesivir and systemic corticosteroids increased from 1.7% and 18.9%, respectively, in March to 53.8% and 74.2%, respectively, in December. Frequency of ICU admission, mechanical ventilation, and vasopressor use decreased from March (37.8%, 27.8%, and 22.7%, respectively) to December (20.5%, 12.3%, and 12.8%, respectively); use of noninvasive respiratory support increased from March to December.LimitationCOVID-NET covers approximately 10% of the U.S. population; findings may not be generalizable to the entire country.ConclusionRates of COVID-19-associated hospitalization, ICU admission, and death were highest in December 2020, corresponding with the third peak of the U.S. pandemic. The frequency of intensive interventions for management of hospitalized patients decreased over time. These data provide a longitudinal assessment of clinical trends among adults hospitalized with COVID-19 before widespread implementation of COVID-19 vaccines.Primary funding sourceCenters for Disease Control and Prevention.
- Published
- 2021
33. Hospitalizations Associated with COVID-19 Among Children and Adolescents - COVID-NET, 14 States, March 1, 2020-August 14, 2021.
- Author
-
Delahoy, Miranda J, Ujamaa, Dawud, Whitaker, Michael, O'Halloran, Alissa, Anglin, Onika, Burns, Erin, Cummings, Charisse, Holstein, Rachel, Kambhampati, Anita K, Milucky, Jennifer, Patel, Kadam, Pham, Huong, Taylor, Christopher A, Chai, Shua J, Reingold, Arthur, Alden, Nisha B, Kawasaki, Breanna, Meek, James, Yousey-Hindes, Kimberly, Anderson, Evan J, Openo, Kyle P, Teno, Kenzie, Weigel, Andy, Kim, Sue, Leegwater, Lauren, Bye, Erica, Como-Sabetti, Kathryn, Ropp, Susan, Rudin, Dominic, Muse, Alison, Spina, Nancy, Bennett, Nancy M, Popham, Kevin, Billing, Laurie M, Shiltz, Eli, Sutton, Melissa, Thomas, Ann, Schaffner, William, Talbot, H Keipp, Crossland, Melanie T, McCaffrey, Keegan, Hall, Aron J, Fry, Alicia M, McMorrow, Meredith, Reed, Carrie, Garg, Shikha, Havers, Fiona P, and COVID-NET Surveillance Team
- Subjects
COVID-NET Surveillance Team ,COVID-NET Surveillance Team ,Humans ,Vaccination ,Hospitalization ,Severity of Illness Index ,Adolescent ,Child ,Child ,Preschool ,Infant ,Infant ,Newborn ,United States ,COVID-19 ,SARS-CoV-2 ,COVID-19 Vaccines ,Rare Diseases ,Prevention ,Pediatric ,General & Internal Medicine - Abstract
Although COVID-19-associated hospitalizations and deaths have occurred more frequently in adults,† COVID-19 can also lead to severe outcomes in children and adolescents (1,2). Schools are opening for in-person learning, and many prekindergarten children are returning to early care and education programs during a time when the number of COVID-19 cases caused by the highly transmissible B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19, is increasing.§ Therefore, it is important to monitor indicators of severe COVID-19 among children and adolescents. This analysis uses Coronavirus Disease 2019-Associated Hospitalization Surveillance Network (COVID-NET)¶ data to describe COVID-19-associated hospitalizations among U.S. children and adolescents aged 0-17 years. During March 1, 2020-August 14, 2021, the cumulative incidence of COVID-19-associated hospitalizations was 49.7 per 100,000 children and adolescents. The weekly COVID-19-associated hospitalization rate per 100,000 children and adolescents during the week ending August 14, 2021 (1.4) was nearly five times the rate during the week ending June 26, 2021 (0.3); among children aged 0-4 years, the weekly hospitalization rate during the week ending August 14, 2021, was nearly 10 times that during the week ending June 26, 2021.** During June 20-July 31, 2021, the hospitalization rate among unvaccinated adolescents (aged 12-17 years) was 10.1 times higher than that among fully vaccinated adolescents. Among all hospitalized children and adolescents with COVID-19, the proportions with indicators of severe disease (such as intensive care unit [ICU] admission) after the Delta variant became predominant (June 20-July 31, 2021) were similar to those earlier in the pandemic (March 1, 2020-June 19, 2021). Implementation of preventive measures to reduce transmission and severe outcomes in children is critical, including vaccination of eligible persons, universal mask wearing in schools, recommended mask wearing by persons aged ≥2 years in other indoor public spaces and child care centers,†† and quarantining as recommended after exposure to persons with COVID-19.§§.
- Published
- 2021
34. Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years - COVID-NET, 13 States, February-April 2021.
- Author
-
Moline, Heidi L, Whitaker, Michael, Deng, Li, Rhodes, Julia C, Milucky, Jennifer, Pham, Huong, Patel, Kadam, Anglin, Onika, Reingold, Arthur, Chai, Shua J, Alden, Nisha B, Kawasaki, Breanna, Meek, James, Yousey-Hindes, Kimberly, Anderson, Evan J, Farley, Monica M, Ryan, Patricia A, Kim, Sue, Nunez, Val Tellez, Como-Sabetti, Kathryn, Lynfield, Ruth, Sosin, Daniel M, McMullen, Chelsea, Muse, Alison, Barney, Grant, Bennett, Nancy M, Bushey, Sophrena, Shiltz, Jessica, Sutton, Melissa, Abdullah, Nasreen, Talbot, H Keipp, Schaffner, William, Chatelain, Ryan, Ortega, Jake, Murthy, Bhavini Patel, Zell, Elizabeth, Schrag, Stephanie J, Taylor, Christopher, Shang, Nong, Verani, Jennifer R, and Havers, Fiona P
- Subjects
Humans ,Vaccines ,Synthetic ,Hospitalization ,Aged ,United States ,COVID-19 ,COVID-19 Vaccines ,Aging ,Prevention ,Vaccine Related ,Immunization ,3.4 Vaccines ,Infection ,General & Internal Medicine - Abstract
Clinical trials of COVID-19 vaccines currently authorized for emergency use in the United States (Pfizer-BioNTech, Moderna, and Janssen [Johnson & Johnson]) indicate that these vaccines have high efficacy against symptomatic disease, including moderate to severe illness (1-3). In addition to clinical trials, real-world assessments of COVID-19 vaccine effectiveness are critical in guiding vaccine policy and building vaccine confidence, particularly among populations at higher risk for more severe illness from COVID-19, including older adults. To determine the real-world effectiveness of the three currently authorized COVID-19 vaccines among persons aged ≥65 years during February 1-April 30, 2021, data on 7,280 patients from the COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) were analyzed with vaccination coverage data from state immunization information systems (IISs) for the COVID-NET catchment area (approximately 4.8 million persons). Among adults aged 65-74 years, effectiveness of full vaccination in preventing COVID-19-associated hospitalization was 96% (95% confidence interval [CI] = 94%-98%) for Pfizer-BioNTech, 96% (95% CI = 95%-98%) for Moderna, and 84% (95% CI = 64%-93%) for Janssen vaccine products. Effectiveness of full vaccination in preventing COVID-19-associated hospitalization among adults aged ≥75 years was 91% (95% CI = 87%-94%) for Pfizer-BioNTech, 96% (95% CI = 93%-98%) for Moderna, and 85% (95% CI = 72%-92%) for Janssen vaccine products. COVID-19 vaccines currently authorized in the United States are highly effective in preventing COVID-19-associated hospitalizations in older adults. In light of real-world data demonstrating high effectiveness of COVID-19 vaccines among older adults, efforts to increase vaccination coverage in this age group are critical to reducing the risk for COVID-19-related hospitalization.
- Published
- 2021
35. Risk Factors for Intensive Care Unit Admission and In-hospital Mortality among Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)
- Author
-
Kim, Lindsay, Garg, Shikha, O’Halloran, Alissa, Whitaker, Michael, Pham, Huong, Anderson, Evan J, Armistead, Isaac, Bennett, Nancy M, Billing, Laurie, Como-Sabetti, Kathryn, Hill, Mary, Kim, Sue, Monroe, Maya L, Muse, Alison, Reingold, Arthur L, Schaffner, William, Sutton, Melissa, Talbot, H Keipp, Torres, Salina M, Yousey-Hindes, Kimberly, Holstein, Rachel, Cummings, Charisse, Brammer, Lynette, Hall, Aron J, Fry, Alicia M, and Langley, Gayle E
- Subjects
Prevention ,Good Health and Well Being ,Adult ,COVID-19 ,Hospital Mortality ,Hospitalization ,Humans ,Intensive Care Units ,Male ,Middle Aged ,Risk Factors ,SARS-CoV-2 ,United States ,hospitalization ,mortality ,surveillance ,Biological Sciences ,Medical and Health Sciences ,Microbiology - Abstract
BackgroundCurrently, the United States has the largest number of reported coronavirus disease 2019 (COVID-19) cases and deaths globally. Using a geographically diverse surveillance network, we describe risk factors for severe outcomes among adults hospitalized with COVID-19.MethodsWe analyzed data from 2491 adults hospitalized with laboratory-confirmed COVID-19 between 1 March-2 May 2020, as identified through the Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, which comprises 154 acute-care hospitals in 74 counties in 13 states. We used multivariable analyses to assess associations between age, sex, race and ethnicity, and underlying conditions with intensive care unit (ICU) admission and in-hospital mortality.ResultsThe data show that 92% of patients had ≥1 underlying condition; 32% required ICU admission; 19% required invasive mechanical ventilation; and 17% died. Independent factors associated with ICU admission included ages 50-64, 65-74, 75-84, and ≥85 years versus 18-39 years (adjusted risk ratios [aRRs], 1.53, 1.65, 1.84, and 1.43, respectively); male sex (aRR, 1.34); obesity (aRR, 1.31); immunosuppression (aRR, 1.29); and diabetes (aRR, 1.13). Independent factors associated with in-hospital mortality included ages 50-64, 65-74, 75-84, and ≥ 85 years versus 18-39 years (aRRs, 3.11, 5.77, 7.67, and 10.98, respectively); male sex (aRR, 1.30); immunosuppression (aRR, 1.39); renal disease (aRR, 1.33); chronic lung disease (aRR 1.31); cardiovascular disease (aRR, 1.28); neurologic disorders (aRR, 1.25); and diabetes (aRR, 1.19).ConclusionsIn-hospital mortality increased markedly with increasing age. Aggressive implementation of prevention strategies, including social distancing and rigorous hand hygiene, may benefit the population as a whole, as well as those at highest risk for COVID-19-related complications.
- Published
- 2021
36. Characteristics of Adults Aged 18–49 Years Without Underlying Conditions Hospitalized With Laboratory-Confirmed Coronavirus Disease 2019 in the United States: COVID-NET—March–August 2020
- Author
-
Owusu, Daniel, Kim, Lindsay, O’Halloran, Alissa, Whitaker, Michael, Piasecki, Alexandra M, Reingold, Arthur, Alden, Nisha B, Maslar, Amber, Anderson, Evan J, Ryan, Patricia A, Kim, Sue, Como-Sabetti, Kathryn, Hancock, Emily B, Muse, Alison, Bennett, Nancy M, Billing, Laurie M, Sutton, Melissa, Talbot, H Keipp, Ortega, Jake, Brammer, Lynnette, Fry, Alicia M, Hall, Aron J, Garg, Shikha, Teama, COVID-NET Surveillance, Cummings, Charisse N, Holstein, Rachel, Kambhampati, Anita, Meador, Seth, Wortham, Jonathan M, Chai, Shua J, Kawasaki, Breanna, Yousey-Hindes, Kimberly, Openo, Kyle P, Monroe, Maya L, Reeg, Libby, Lynfield, Ruth, Eisenberg, Nancy, Barney, Grant R, Felsen, Christina B, Shiltz, Jessica, West, Nicole, Schaffner, William, and Price, Andrea
- Subjects
Good Health and Well Being ,Adolescent ,Adult ,COVID-19 ,Hospitalization ,Humans ,Intensive Care Units ,Laboratories ,Middle Aged ,SARS-CoV-2 ,United States ,Young Adult ,COVID-NET ,hospitalization ,young adults ,COVID-NET Surveillance Teama ,Biological Sciences ,Medical and Health Sciences ,Microbiology - Abstract
Among 513 adults aged 18-49 years without underlying medical conditions hospitalized with coronavirus disease 2019 (COVID-19) during March 2020-August 2020, 22% were admitted to an intensive care unit, 10% required mechanical ventilation, and 3 patients died (0.6%). These data demonstrate that healthy younger adults can develop severe COVID-19.
- Published
- 2021
37. Piloting an integrated SARS-CoV-2 testing and data system for outbreak containment among college students: A prospective cohort study.
- Author
-
Packel, Laura, Reingold, Arthur, Hunter, Lauren, Facente, Shelley, Li, Yi, Harte, Anna, Nicolette, Guy, Urnov, Fyodor D, Lu, Michael, Petersen, Maya, and IGI Testing Consortium
- Subjects
IGI Testing Consortium ,Humans ,Contact Tracing ,Cohort Studies ,Prospective Studies ,Communicable Disease Control ,Students ,Universities ,California ,Surveys and Questionnaires ,COVID-19 ,SARS-CoV-2 ,COVID-19 Nucleic Acid Testing ,General Science & Technology - Abstract
BackgroundColleges and universities across the country are struggling to develop strategies for effective control of COVID-19 transmission as students return to campus.Methods and findingsWe conducted a prospective cohort study with students living on or near the UC Berkeley campus from June 1st through August 18th, 2020 with the goal of providing guidance for campus reopening in the safest possible manner. In this cohort, we piloted an alternative testing model to provide access to low-barrier, high-touch testing and augment student-driven testing with data-driven adaptive surveillance that targets higher-risk students and triggers testing notifications based on reported symptoms, exposures, or other relevant information. A total of 2,180 students enrolled in the study, 51% of them undergraduates. Overall, 6,247 PCR tests were administered to 2,178 students over the two-month period. Overall test positivity rate was 0.9%; 2.6% of students tested positive. Uptake and acceptability of regular symptom and exposure surveys was high; 98% of students completed at least one survey, and average completion rate was 67% (Median: 74%, IQR: 39%) for daily reporting of symptoms and 68% (Median: 75%, IQR: 40%) for weekly reporting of exposures. Of symptom-triggered tests, 5% were PCR-positive; of exposure-triggered tests, 10% were PCR-positive. The integrated study database augmented traditional contact tracing during an outbreak; 17 potentially exposed students were contacted the following day and sent testing notifications. At study end, 81% of students selected their desire "to contribute to UC Berkeley's response to COVID-19" as a reason for their participation in the Safe Campus study.ConclusionsOur results illustrate the synergy created by bringing together a student-friendly, harm reduction approach to COVID-19 testing with an integrated data system and analytics. We recommend the use of a confidential, consequence-free, incentive-based daily symptom and exposure reporting system, coupled with low-barrier, easy access, no stigma testing. Testing should be implemented alongside a system that integrates multiple data sources to effectively trigger testing notifications to those at higher risk of infection and encourages students to come in for low-barrier testing when needed.
- Published
- 2021
38. Census tract socioeconomic indicators and COVID-19-associated hospitalization rates-COVID-NET surveillance areas in 14 states, March 1-April 30, 2020.
- Author
-
Wortham, Jonathan M, Meador, Seth A, Hadler, James L, Yousey-Hindes, Kimberly, See, Isaac, Whitaker, Michael, O'Halloran, Alissa, Milucky, Jennifer, Chai, Shua J, Reingold, Arthur, Alden, Nisha B, Kawasaki, Breanna, Anderson, Evan J, Openo, Kyle P, Weigel, Andrew, Monroe, Maya L, Ryan, Patricia A, Kim, Sue, Reeg, Libby, Lynfield, Ruth, McMahon, Melissa, Sosin, Daniel M, Eisenberg, Nancy, Rowe, Adam, Barney, Grant, Bennett, Nancy M, Bushey, Sophrena, Billing, Laurie M, Shiltz, Jess, Sutton, Melissa, West, Nicole, Talbot, H Keipp, Schaffner, William, McCaffrey, Keegan, Spencer, Melanie, Kambhampati, Anita K, Anglin, Onika, Piasecki, Alexandra M, Holstein, Rachel, Hall, Aron J, Fry, Alicia M, Garg, Shikha, and Kim, Lindsay
- Subjects
Prevention ,Behavioral and Social Science ,General Science & Technology - Abstract
ObjectivesSome studies suggested more COVID-19-associated hospitalizations among racial and ethnic minorities. To inform public health practice, the COVID-19-associated Hospitalization Surveillance Network (COVID-NET) quantified associations between race/ethnicity, census tract socioeconomic indicators, and COVID-19-associated hospitalization rates.MethodsUsing data from COVID-NET population-based surveillance reported during March 1-April 30, 2020 along with socioeconomic and denominator data from the US Census Bureau, we calculated COVID-19-associated hospitalization rates by racial/ethnic and census tract-level socioeconomic strata.ResultsAmong 16,000 COVID-19-associated hospitalizations, 34.8% occurred among non-Hispanic White (White) persons, 36.3% among non-Hispanic Black (Black) persons, and 18.2% among Hispanic or Latino (Hispanic) persons. Age-adjusted COVID-19-associated hospitalization rate were 151.6 (95% Confidence Interval (CI): 147.1-156.1) in census tracts with >15.2%-83.2% of persons living below the federal poverty level (high-poverty census tracts) and 75.5 (95% CI: 72.9-78.1) in census tracts with 0%-4.9% of persons living below the federal poverty level (low-poverty census tracts). Among White, Black, and Hispanic persons living in high-poverty census tracts, age-adjusted hospitalization rates were 120.3 (95% CI: 112.3-128.2), 252.2 (95% CI: 241.4-263.0), and 341.1 (95% CI: 317.3-365.0), respectively, compared with 58.2 (95% CI: 55.4-61.1), 304.0 (95%: 282.4-325.6), and 540.3 (95% CI: 477.0-603.6), respectively, in low-poverty census tracts.ConclusionsOverall, COVID-19-associated hospitalization rates were highest in high-poverty census tracts, but rates among Black and Hispanic persons were high regardless of poverty level. Public health practitioners must ensure mitigation measures and vaccination campaigns address needs of racial/ethnic minority groups and people living in high-poverty census tracts.
- Published
- 2021
39. Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated Hospitalizations Among Children Aged <2 Years in the United States, 2014-15.
- Author
-
Arriola, Carmen, Kim, Lindsay, Langley, Gayle, Anderson, Evan, Openo, Kyle, Martin, Andrew, Lynfield, Ruth, Bye, Erica, Como-Sabetti, Kathy, Chai, Shua, Daily, Pam, Thomas, Ann, Crawford, Courtney, Reed, C, Garg, S, Chaves, Sandra, and Reingold, Arthur
- Subjects
RSV ,children ,disease burden ,Age Factors ,Community-Acquired Infections ,Female ,Hospitalization ,Humans ,Infant ,Infant ,Newborn ,Influenza ,Human ,Intensive Care Units ,Male ,Population Surveillance ,Respiration ,Artificial ,Respiratory Syncytial Virus Infections ,Respiratory Syncytial Virus ,Human ,Risk Factors ,United States - Abstract
BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of hospitalizations in young children. We estimated the burden of community-onset RSV-associated hospitalizations among US children aged
- Published
- 2020
40. Evaluation of a city-wide school-located influenza vaccination program in Oakland, California, with respect to vaccination coverage, school absences, and laboratory-confirmed influenza: A matched cohort study.
- Author
-
Benjamin-Chung, Jade, Arnold, Benjamin F, Kennedy, Chris J, Mishra, Kunal, Pokpongkiat, Nolan, Nguyen, Anna, Jilek, Wendy, Holbrook, Kate, Pan, Erica, Kirley, Pam D, Libby, Tanya, Hubbard, Alan E, Reingold, Arthur, and Colford, John M
- Subjects
Humans ,Influenza Vaccines ,Vaccination ,Cohort Studies ,Cross-Sectional Studies ,Absenteeism ,Schools ,Students ,Adolescent ,Child ,Child ,Preschool ,Urban Population ,School Health Services ,California ,Female ,Male ,Influenza ,Human ,Vaccination Coverage ,General & Internal Medicine ,Medical and Health Sciences - Abstract
BACKGROUND:It is estimated that vaccinating 50%-70% of school-aged children for influenza can produce population-wide indirect effects. We evaluated a city-wide school-located influenza vaccination (SLIV) intervention that aimed to increase influenza vaccination coverage. The intervention was implemented in ≥95 preschools and elementary schools in northern California from 2014 to 2018. Using a matched cohort design, we estimated intervention impacts on student influenza vaccination coverage, school absenteeism, and community-wide indirect effects on laboratory-confirmed influenza hospitalizations. METHODS AND FINDINGS:We used a multivariate matching algorithm to identify a nearby comparison school district with pre-intervention characteristics similar to those of the intervention school district and matched schools in each district. To measure student influenza vaccination, we conducted cross-sectional surveys of student caregivers in 22 school pairs (2017 survey, N = 6,070; 2018 survey, N = 6,507). We estimated the incidence of laboratory-confirmed influenza hospitalization from 2011 to 2018 using surveillance data from school district zip codes. We analyzed student absenteeism data from 2011 to 2018 from each district (N = 42,487,816 student-days). To account for pre-intervention differences between districts, we estimated difference-in-differences (DID) in influenza hospitalization incidence and absenteeism rates using generalized linear and log-linear models with a population offset for incidence outcomes. Prior to the SLIV intervention, the median household income was $51,849 in the intervention site and $61,596 in the comparison site. The population in each site was predominately white (41% in the intervention site, 48% in the comparison site) and/or of Hispanic or Latino ethnicity (26% in the intervention site, 33% in the comparison site). The number of students vaccinated by the SLIV intervention ranged from 7,502 to 10,106 (22%-28% of eligible students) each year. During the intervention, influenza vaccination coverage among elementary students was 53%-66% in the comparison district. Coverage was similar between the intervention and comparison districts in influenza seasons 2014-2015 and 2015-2016 and was significantly higher in the intervention site in seasons 2016-2017 (7%; 95% CI 4, 11; p < 0.001) and 2017-2018 (11%; 95% CI 7, 15; p < 0.001). During seasons when vaccination coverage was higher among intervention schools and the vaccine was moderately effective, there was evidence of statistically significant indirect effects: The DID in the incidence of influenza hospitalization per 100,000 in the intervention versus comparison site was -17 (95% CI -30, -4; p = 0.008) in 2016-2017 and -37 (95% CI -54, -19; p < 0.001) in 2017-2018 among non-elementary-school-aged individuals and -73 (95% CI -147, 1; p = 0.054) in 2016-2017 and -160 (95% CI -267, -53; p = 0.004) in 2017-2018 among adults 65 years or older. The DID in illness-related school absences per 100 school days during the influenza season was -0.63 (95% CI -1.14, -0.13; p = 0.014) in 2016-2017 and -0.80 (95% CI -1.28, -0.31; p = 0.001) in 2017-2018. Limitations of this study include the use of an observational design, which may be subject to unmeasured confounding, and caregiver-reported vaccination status, which is subject to poor recall and low response rates. CONCLUSIONS:A city-wide SLIV intervention in a large, diverse urban population was associated with a decrease in the incidence of laboratory-confirmed influenza hospitalization in all age groups and a decrease in illness-specific school absence rate among students in 2016-2017 and 2017-2018, seasons when the vaccine was moderately effective, suggesting that the intervention produced indirect effects. Our findings suggest that in populations with moderately high background levels of influenza vaccination coverage, SLIV programs are associated with further increases in coverage and reduced influenza across the community.
- Published
- 2020
41. Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 1-July 25, 2020.
- Author
-
Kim, Lindsay, Whitaker, Michael, O'Halloran, Alissa, Kambhampati, Anita, Chai, Shua J, Reingold, Arthur, Armistead, Isaac, Kawasaki, Breanna, Meek, James, Yousey-Hindes, Kimberly, Anderson, Evan J, Openo, Kyle P, Weigel, Andy, Ryan, Patricia, Monroe, Maya L, Fox, Kimberly, Kim, Sue, Lynfield, Ruth, Bye, Erica, Shrum Davis, Sarah, Smelser, Chad, Barney, Grant, Spina, Nancy L, Bennett, Nancy M, Felsen, Christina B, Billing, Laurie M, Shiltz, Jessica, Sutton, Melissa, West, Nicole, Talbot, H Keipp, Schaffner, William, Risk, Ilene, Price, Andrea, Brammer, Lynnette, Fry, Alicia M, Hall, Aron J, Langley, Gayle E, Garg, Shikha, and COVID-NET Surveillance Team
- Subjects
COVID-NET Surveillance Team ,Humans ,Pneumonia ,Viral ,Coronavirus Infections ,Chronic Disease ,Hospitalization ,Severity of Illness Index ,Risk Factors ,Adolescent ,Child ,Child ,Preschool ,Infant ,Infant ,Newborn ,Ethnic Groups ,United States ,Female ,Male ,Pandemics ,Clinical Laboratory Services ,Pediatric Obesity ,Betacoronavirus ,COVID-19 ,SARS-CoV-2 ,General & Internal Medicine - Abstract
Most reported cases of coronavirus disease 2019 (COVID-19) in children aged
- Published
- 2020
42. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis
- Author
-
Martinez, Leonardo, Cords, Olivia, Horsburgh, C Robert, Andrews, Jason R, Consortium, Pediatric TB Contact Studies, Acuna-Villaorduna, Carlos, Ahuja, Shama Desai, Altet, Neus, Augusto, Orvalho, Baliashvili, Davit, Basu, Sanjay, Becerra, Mercedes, Bonnet, Maryline, Boom, W Henry, Borgdorff, Martien, Boulahbal, Fadila, Carvalho, Anna Cristina C, Cayla, Joan A, Chakhaia, Tsira, Chan, Pei-Chun, Cohen, Ted, Croda, Julio, Datta, Sumona, del Corral, Helena, Denholm, Justin T, Dietze, Reynaldo, Dobler, Claudia C, Donkor, Simon, Egere, Uzochukwu, Ellner, Jerrold J, Espinal, Marcos, Evans, Carlton A, Fang, Chi-Tai, Fielding, Katherine, Fox, Greg J, García, Luis F, García-Basteiro, Alberto L, Geis, Steffen, Graham, Stephen M, Grandjean, Louis, Hannoun, Djohar, Hatherill, Mark, Hauri, Anja M, Hesseling, Anneke C, Hill, Philip C, Huang, Li-Min, Huerga, Helena, Hussain, Rabia, Jarlsberg, Leah, Jones-López, Edward C, Kato, Seiya, Kato-Maeda, Midori, Kampmann, Beate, Kirchner, H Lester, Kritski, Afrânio, Lange, Christoph, Lee, Chih-Hsin, Lee, Li-Na, Lee, Meng-Rui, Lemos, Antonio Carlos, Lienhardt, Christian, Ling, Du-Lin, Liu, Qiao, Lo, Nathan C, Long, Richard, Lopez-Varela, Elisa, Lu, Peng, Magee, Matthew, Malone, LaShaunda L, Mandalakas, Anna M, Martinson, Neil A, Mazahir, Rufaida, Murray, Megan B, Netto, Eduardo Martins, Otero, Larissa, Parsonnet, Julie, Reingold, Arthur, Schaaf, H Simon, Seddon, James A, Sharma, Surendra, Singh, Jitendra, Singh, Sarman, Sloot, Rosa, Sotgiu, Giovanni, Stein, Catherine M, Iqbal, Najeeha Talat, Triasih, Rina, Trieu, Lisa, van der Loeff, Maarten F Schim, Van der Stuyft, Patrick, van Schalkwyk, Cari, Vashishtha, Richa, Verhagen, Lilly M, Villalba, Julian A, Wang, Jann-Yuan, Whalen, Christopher C, Yoshiyama, Takashi, Zar, Heather J, Zellweger, Jean-Pierre, and Zhu, Limei
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,Tuberculosis ,Prevention ,Rare Diseases ,Pediatric ,Infectious Diseases ,Emerging Infectious Diseases ,Infection ,Good Health and Well Being ,Adolescent ,Age Factors ,Child ,Child ,Preschool ,Contact Tracing ,Disease Transmission ,Infectious ,Family Characteristics ,Female ,Global Health ,Humans ,Incidence ,Male ,Mycobacterium tuberculosis ,Risk Assessment ,Sex Factors ,Tuberculosis ,Pulmonary ,Pediatric TB Contact Studies Consortium ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundTens of millions of children are exposed to Mycobacterium tuberculosis globally every year; however, there are no contemporary estimates of the risk of developing tuberculosis in exposed children. The effectiveness of contact investigations and preventive therapy remains poorly understood.MethodsIn this systematic review and meta-analysis, we investigated the development of tuberculosis in children closely exposed to a tuberculosis case and followed for incident disease. We restricted our search to cohort studies published between Jan 1, 1998, and April 6, 2018, in MEDLINE, Web of Science, BIOSIS, and Embase electronic databases. Individual-participant data and a pre-specified list of variables were requested from authors of all eligible studies. These included characteristics of the exposed child, the index case, and environmental characteristics. To be eligible for inclusion in the final analysis, a dataset needed to include: (1) individuals below 19 years of age; (2) follow-up for tuberculosis for a minimum of 6 months; (3) individuals with household or close exposure to an individual with tuberculosis; (4) information on the age and sex of the child; and (5) start and end follow-up dates. Studies assessing incident tuberculosis but without dates or time of follow-up were excluded. Our analysis had two primary aims: (1) estimating the risk of developing tuberculosis by time-period of follow-up, demographics (age, region), and clinical attributes (HIV, tuberculosis infection status, previous tuberculosis); and (2) estimating the effectiveness of preventive therapy and BCG vaccination on the risk of developing tuberculosis. We estimated the odds of prevalent tuberculosis with mixed-effects logistic models and estimated adjusted hazard ratios (HRs) for incident tuberculosis with mixed-effects Poisson regression models. The effectiveness of preventive therapy against incident tuberculosis was estimated through propensity score matching. The study protocol is registered with PROSPERO (CRD42018087022).FindingsIn total, study groups from 46 cohort studies in 34 countries-29 (63%) prospective studies and 17 (37%) retrospective-agreed to share their data and were included in the final analysis. 137 647 tuberculosis-exposed children were evaluated at baseline and 130 512 children were followed for 429 538 person-years, during which 1299 prevalent and 999 incident tuberculosis cases were diagnosed. Children not receiving preventive therapy with a positive result for tuberculosis infection had significantly higher 2-year cumulative tuberculosis incidence than children with a negative result for tuberculosis infection, and this incidence was greatest among children below 5 years of age (19·0% [95% CI 8·4-37·4]). The effectiveness of preventive therapy was 63% (adjusted HR 0·37 [95% CI 0·30-0·47]) among all exposed children, and 91% (adjusted HR 0·09 [0·05-0·15]) among those with a positive result for tuberculosis infection. Among all children
- Published
- 2020
43. Impact of a city-wide school-located influenza vaccination program over four years on vaccination coverage, school absences, and laboratory-confirmed influenza: a prospective matched cohort study
- Author
-
Benjamin-Chung, Jade, Arnold, Benjamin F, Kennedy, Chris J, Mishra, Kunal, Pokpongkiat, Nolan, Nguyen, Anna, Jilek, Wendy, Holbrook, Kate, Pan, Erica, Kirley, Pam D, Libby, Tanya, Hubbard, Alan E, Reingold, Arthur, and Colford, John M
- Subjects
Prevention ,Influenza ,Clinical Research ,Immunization ,Vaccine Related ,Pneumonia & Influenza ,Infectious Diseases ,Prevention of disease and conditions ,and promotion of well-being ,3.4 Vaccines ,Infection ,Good Health and Well Being - Abstract
AbstractBackgroundIt is estimated that vaccinating 50-70% of school-aged children for influenza can produce population-wide indirect effects. We evaluated a city-wide, school-located influenza vaccination (SLIV) intervention that aimed to increase influenza vaccination coverage. The intervention was implemented in over 95 pre-schools and elementary schools in northern California from 2014 to 2018. Using a matched prospective cohort design, we estimated intervention impacts on student influenza vaccination coverage, school absenteeism, and community-wide indirect effects on laboratory-confirmed influenza hospitalizations.Methods and FindingsWe used a multivariate matching algorithm to identify a nearby comparison school district with similar pre-intervention characteristics and matched schools in each district. To measure student influenza vaccination, we conducted cross-sectional surveys of student caregivers in 22 school pairs (2016 survey N = 6,070; 2017 survey N = 6,507). We estimated the incidence of laboratory-confirmed influenza hospitalization from 2011-2018 using surveillance data from school district zip codes. We analyzed student absenteeism data from 2011-2018 from each district (N = 42,487,816 student-days). To account for pre-intervention differences between districts, we estimated difference-in-differences (DID) in influenza hospitalization incidence and absenteeism rates using generalized linear and log-linear models with a population offset for incidence outcomes.The number of students vaccinated by the SLIV intervention ranged from 7,502 to 10,106 (22-28% of eligible students) each year. During the intervention, influenza vaccination coverage among elementary students was 53-66% in the comparison district. Coverage was similar between the intervention and comparison districts in 2014-15 and 2015-16 and was significantly higher in the intervention site in 2016-17 (7% 95% CI 4, 11) and 2017-18 (11% 95% CI 7, 15). During seasons when vaccination coverage was higher among intervention schools and the vaccine was moderately effective, there was evidence of statistically significant indirect effects: adjusting for pre-intervention differences between districts, the reduction in influenza hospitalizations in the intervention site was 76 (95% CI 20, 133) in 2016-17 and 165 (95% CI 86, 243) in 2017-18 among non-elementary school aged individuals and 327 (5, 659) in 2016-17 and 715 (236, 1195) in 2017-18 among adults 65 years or older. The reduction in illness-related school absences during influenza season was 3,538 (95% CI 709, 6,366) in 2016-17 and 8,249 (95% CI 3,213, 13,285) in 2017-18. Limitations of this study include the use of an observational design, which may be subject to unmeasured confounding, and caregiver-reported vaccination status, which is subject to poor recall and low response rates.ConclusionA city-wide SLIV intervention in a large, diverse urban population decreased the incidence of laboratory-confirmed influenza hospitalization in all age groups and decreased illness-specific school absence rates among students during seasons when the vaccine was moderately effective, suggesting that the intervention produced indirect effects. Our findings suggest that in populations with moderately high background levels of influenza vaccination coverage, SLIV programs can further increase coverage and reduce influenza across communities.
- Published
- 2019
44. The impact of pneumococcal serotype replacement on the effectiveness of a national immunization program: a population-based active surveillance cohort study in New Zealand
- Author
-
Anglemyer, Andrew, primary, Ren, Xiaoyun, additional, Gilkison, Charlotte, additional, Kumbaroff, Zoe, additional, Morgan, Julie, additional, DuBray, Kara, additional, Tiong, Audrey, additional, Reingold, Arthur, additional, and Walls, Tony, additional
- Published
- 2024
- Full Text
- View/download PDF
45. Emerging Challenges and Opportunities in Infectious Disease Epidemiology
- Author
-
Lewnard, Joseph A and Reingold, Arthur L
- Subjects
Infectious Diseases ,2.1 Biological and endogenous factors ,Aetiology ,Infection ,Good Health and Well Being ,Anti-Infective Agents ,Causality ,Communicable Disease Control ,Communicable Diseases ,Data Interpretation ,Statistical ,Disaster Planning ,Epidemiologic Methods ,Humans ,Observational Studies as Topic ,Population Surveillance ,Public Health Practice ,United Kingdom ,United States ,Vaccines ,infectious diseases ,methods ,modeling ,surveillance ,Mathematical Sciences ,Medical and Health Sciences ,Epidemiology - Abstract
Much of the intellectual tradition of modern epidemiology stems from efforts to understand and combat chronic diseases persisting through the 20th century epidemiologic transition of countries such as the United States and United Kingdom. After decades of relative obscurity, infectious disease epidemiology has undergone an intellectual rebirth in recent years amid increasing recognition of the threat posed by both new and familiar pathogens. Here, we review the emerging coalescence of infectious disease epidemiology around a core set of study designs and statistical methods bearing little resemblance to the chronic disease epidemiology toolkit. We offer our outlook on challenges and opportunities facing the field, including the integration of novel molecular and digital information sources into disease surveillance, the assimilation of such data into models of pathogen spread, and the increasing contribution of models to public health practice. We next consider emerging paradigms in causal inference for infectious diseases, ranging from approaches to evaluating vaccines and antimicrobial therapies to the task of ascribing clinical syndromes to etiologic microorganisms, an age-old problem transformed by our increasing ability to characterize human-associated microbiota. These areas represent an increasingly important component of epidemiology training programs for future generations of researchers and practitioners.
- Published
- 2019
46. Sex differences and correlates of poor glycaemic control in type 2 diabetes: a cross-sectional study in Brazil and Venezuela.
- Author
-
G Duarte, Fernanda, da Silva Moreira, Sandra, Almeida, Maria, de Souza Teles, Carlos, Andrade, Carine, REINGOLD, Arthur L., and Moreira, Edson
- Subjects
gender ,glycemic control ,type 2 diabetes ,Adolescent ,Adult ,Aged ,Blood Glucose ,Brazil ,Cross-Sectional Studies ,Diabetes Mellitus ,Type 2 ,Female ,Glycated Hemoglobin A ,Humans ,Hypoglycemic Agents ,Linear Models ,Male ,Middle Aged ,Multivariate Analysis ,Self Report ,Sex Factors ,Treatment Outcome ,Venezuela ,Young Adult - Abstract
OBJECTIVE: Examine whether glycaemic control varies according to sex and whether the latter plays a role in modifying factors associated with inadequate glycaemic control in patients with type 2 diabetes (T2D) in Brazil and Venezuela. DESIGN, SETTING AND PARTICIPANTS: This was a cross-sectional, nationwide survey conducted in Brazil and Venezuela from February 2006 to June 2007 to obtain information about glycaemic control and its determinants in patients with diabetes mellitus attending outpatient clinics. MAIN OUTCOME MEASURES: Haemoglobin A1c (HbA1c) level was measured by liquid chromatography, and patients with HbA1c ≥7.0% (53 mmol/mol) were considered to have inadequate glycaemic control. The association of selected variables with glycaemic control was analysed by multivariate linear regression, using HbA1c as the dependent variable. RESULTS: A total of 9418 patients with T2D were enrolled in Brazil (n=5692) and in Venezuela (n=3726). They included 6214 (66%) women and 3204 (34%) men. On average, HbA1c levels in women were 0.13 (95% CI 0.03 to 0.24; p=0.015) higher than in men, after adjusting for age, marital status, education, race, country, body mass index, duration of disease, complications, type of healthcare, adherence to diet, adherence to treatment and previous measurement of HbA1c. Sex modified the effect of some factors associated with glycaemic control in patients with T2D in our study, but had no noteworthy effect in others. CONCLUSIONS: Women with T2D had worse glycaemic control than men. Possible causes for poorer glycaemic control in women compared with men include differences in glucose homeostasis, treatment response and psychological factors. In addition, sex modified factors associated with glycaemic control, suggesting the need to develop specific treatment guidelines for men and women.
- Published
- 2019
47. Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies
- Author
-
Dorjee, Kunchok, Choden, Tsering, Baxi, Sanjiv M, Steinmaus, Craig, and Reingold, Arthur L
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Cardiovascular ,Prevention ,HIV/AIDS ,Heart Disease ,Good Health and Well Being ,Adult ,Aged ,Aged ,80 and over ,Anti-HIV Agents ,Cardiovascular Diseases ,Dideoxynucleosides ,Female ,HIV Infections ,Humans ,Male ,Middle Aged ,Risk Assessment ,Young Adult ,Abacavir ,Human immunodeficiency virus ,Cardiovascular disease ,Pharmacology and Pharmaceutical Sciences ,Microbiology ,Medical microbiology - Abstract
ObjectivesAbacavir's potential to cause cardiovascular disease (CVD) among people living with HIV (PLWH) is debated. We conduct a systematic review and meta-analyses to assess CVD risk from recent and cumulative abacavir exposure.MethodsWe searched Medline, Embase, Web of Science, abstracts from Conference on Retroviruses and Opportunistic Infections, and International AIDS Society/AIDS Conferences and bibliographies of review articles to identify research studies published through 2018 on CVD risk associated with abacavir exposure among PLWH. Studies assessing risk of CVD associated with recent (exposure within last 6 months) or cumulative abacavir exposure across all age-groups were eligible. Risks were quantified using fixed- and random-effects models.ResultsOf 378 unique citations, 68 full-text research articles and abstracts were reviewed. Seventeen studies assessed risk of CVD from recent or cumulative abacavir exposure. Summary relative risk (sRR) is increased for recent exposure (n=16 studies, sRR=1.61; 95% confidence interval: 1.48-1.75), higher in antiretroviral-therapy-naive population (n=5, 1.91; 1.48-2.46) and all studies reported RR>1. The sRR for recent exposure was similarly increased for the outcome of acute myocardial infarction, and for studies that adjusted for substance abuse, smoking, prior CVD, traditional CVD risk factors, and CD4 cell-count/HIV viral load. The sRR was increased for cumulative abacavir exposure (per year) (n=4, 1.12; 1.05-1.20) but no increase was seen after adjusting for recent exposure (n=5, 1.00; 0.93-1.08).ConclusionsOur findings suggest an increased risk of CVD from recent abacavir exposure. The risk remained elevated after adjusting for potential confounders. Further investigations are needed to understand CVD risk from cumulative exposure.
- Published
- 2018
48. Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study.
- Author
-
Cardoso, Clareci Silva, Ribeiro, Antonio Luiz P, Oliveira, Claudia Di Lorenzo, Oliveira, Lea Campos, Ferreira, Ariela Mota, Bierrenbach, Ana Luiza, Silva, José Luiz Padilha, Colosimo, Enrico Antonio, Ferreira, João Eduardo, Lee, Tzong-Hae, Busch, Michael P, Reingold, Arthur Lawrence, and Sabino, Ester Cerdeira
- Subjects
Humans ,Trypanosoma cruzi ,Parasitemia ,Chagas Disease ,Chronic Disease ,Nitroimidazoles ,Trypanocidal Agents ,Aftercare ,Follow-Up Studies ,Prospective Studies ,National Institutes of Health (U.S.) ,United States ,Brazil ,National Institutes of Health ,Tropical Medicine ,Biological Sciences ,Medical and Health Sciences - Abstract
BackgroundThe effectiveness of anti-parasite treatment with benznidazole in the chronic Chagas disease (ChD) remains uncertain. We evaluated, using data from the NIH-sponsored SaMi-Trop prospective cohort study, if previous treatment with benznidazole is associated with lower mortality, less advanced cardiac disease and lower parasitemia in patients with chronic ChD.MethodsThe study enrolled 1,959 ChD patients and abnormal electrocardiogram (ECG) from in 21 remote towns in Brazil. A total of 1,813 patients were evaluated at baseline and after two years of follow-up. Those who received at least one course of benznidazole were classified as treated group (TrG = 493) and those who were never treated as control group (CG = 1,320). The primary outcome was death after two-year follow-up; the secondary outcomes were presence at the baseline of major ChD-associated ECG abnormalities, NT-ProBNP levels suggestive of heart failure, and PCR positivity.ResultsMortality after two years was 6.3%; it was lower in the TrG (2.8%) than the CG (7.6%); adjusted OR: 0.37 (95%CI: 0.21;0.63). The ECG abnormalities typical for ChD and high age-adjusted NT-ProBNP levels suggestive of heart failure were lower in the TrG than the CG, OR: 0.35 [CI: 0.23;0.53]. The TrG had significantly lower rates of PCR positivity, OR: 0.35 [CI: 0.27;0.45].ConclusionPatients previously treated with benznidazole had significantly reduced parasitemia, a lower prevalence of markers of severe cardiomyopathy, and lower mortality after two years of follow-up. If used in the early phases, benznidazole treatment may improve clinical and parasitological outcomes in patients with chronic ChD.Trial registrationClinicalTrials.gov, Trial registration: NCT02646943.
- Published
- 2018
49. Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis
- Author
-
Martinez, Leonardo, Cords, Olivia, Liu, Qiao, Acuna-Villaorduna, Carlos, Bonnet, Maryline, Fox, Greg J, Carvalho, Anna Cristina C, Chan, Pei-Chun, Croda, Julio, Hill, Philip C, Lopez-Varela, Elisa, Donkor, Simon, Fielding, Katherine, Graham, Stephen M, Espinal, Marcos A, Kampmann, Beate, Reingold, Arthur, Huerga, Helena, Villalba, Julian A, Grandjean, Louis, Sotgiu, Giovanni, Egere, Uzochukwu, Singh, Sarman, Zhu, Limei, Lienhardt, Christian, Denholm, Justin T, Seddon, James A, Whalen, Christopher C, García-Basteiro, Alberto L, Triasih, Rina, Chen, Cheng, Singh, Jitendra, Huang, Li-Min, Sharma, Surendra, Hannoun, Djohar, del Corral, Helena, Mandalakas, Anna M, Malone, LaShaunda L, Ling, Du-Lin, Kritski, Afrânio, Stein, Catherine M, Vashishtha, Richa, Boulahbal, Fadila, Fang, Chi-Tai, Boom, W Henry, Netto, Eduardo Martins, Lemos, Antonio Carlos, Hesseling, Anneke C, Kay, Alexander, Jones-López, Edward C, Horsburgh, C Robert, Lange, Christoph, and Andrews, Jason R
- Published
- 2022
- Full Text
- View/download PDF
50. Current Epidemiology and Trends in Invasive Haemophilus influenzae Disease-United States, 2009-2015.
- Author
-
Soeters, Heidi M, Blain, Amy, Pondo, Tracy, Doman, Brooke, Farley, Monica M, Harrison, Lee H, Lynfield, Ruth, Miller, Lisa, Petit, Susan, Reingold, Arthur, Schaffner, William, Thomas, Ann, Zansky, Shelley M, Wang, Xin, and Briere, Elizabeth C
- Subjects
Pediatric ,Immunization ,Prevention ,Vaccine Related ,Infectious Diseases ,Emerging Infectious Diseases ,Clinical Research ,2.4 Surveillance and distribution ,Aetiology ,Good Health and Well Being ,Adolescent ,Adult ,Age Factors ,Aged ,Child ,Child ,Preschool ,Cost of Illness ,Epidemiological Monitoring ,Female ,Haemophilus Infections ,Haemophilus Vaccines ,Haemophilus influenzae ,Haemophilus influenzae type b ,Humans ,Incidence ,Infant ,Infant ,Newborn ,Male ,Middle Aged ,Public Health ,Serotyping ,United States ,Young Adult ,invasive disease ,surveillance ,epidemiology ,Biological Sciences ,Medical and Health Sciences ,Microbiology - Abstract
BackgroundFollowing Haemophilus influenzae serotype b (Hib) conjugate vaccine introduction in the 1980s, Hib disease in young children dramatically decreased, and epidemiology of invasive H. influenzae changed.MethodsActive surveillance for invasive H. influenzae disease was conducted through Active Bacterial Core surveillance sites. Incidence rates were directly standardized to the age and race distribution of the US population.ResultsDuring 2009-2015, the estimated mean annual incidence of invasive H. influenzae disease was 1.70 cases per 100000 population. Incidence was highest among adults aged ≥65 years (6.30) and children aged
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.